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EFFECTS OF ANTI-Aß MONOCLONAL ANTIBODIES ON THE AMYLOID 
BETA PEPTIDE FIBRILLOGENESIS AND THEIR INVOLVEMENT IN THE 
CLEARANCE OF ALZHEIMER’S DISEASE PLAQUES  
 
Jeffy Pilar Jiménez 
 
ABSTRACT  
 
Alzheimer’s disease (AD) is the most common cause of senile dementia 
worldwide. AD is a neurodegenerative disorder characterized by the loss of 
memory and language skill, collapse of the cognitive function, and distortion of 
social behavior.   As of today, the onset mechanisms of AD and cure are 
unknown; however, three hallmarks are commonly encountered: extra and 
intracellular accumulation of amyloid beta (A!) peptide plaques, formation of 
intracellular neurofibrillary tangles, and inevitable neuronal death.  Hypothetically, 
a possible scenario provoking or involved in the onset of AD is a cascade effect 
that starts with an imbalance in the production and clearance of Aß peptide that 
consequently leads to its accumulation, formation of tau protein tangles and 
neuronal death. This work studied and characterized the mechanisms governing 
A! peptide aggregation and the effects of using anti-Aß monoclonal antibodies to 
modify this process.  These mechanisms play an important role in the formation 
 xiv 
of AD plaques and are critical in the search for therapies involving Aß peptide 
plaque clearance. Yet, antibody-based therapies for plaque clearance are not 
well understood, adding to the existing concerns about side effects in humans, 
hence there is a necessity of knowledge in this matter. In this work different N-
terminus, C-terminus, and Mid-domain antibodies were used against Aß peptide 
species (monomers, oligomers, and fibrils) to probe peptide aggregates 
modification and disruption. Additionally, construction of a soft supported lipid 
bilayer membrane was proposed to study the adhesion mechanisms of Aß 
peptide and interactions with antibodies, mimicking the neuronal cell surface. The 
main characterization techniques used in this work were:  atomic force 
microscopy (AFM) and transmission electron microscopy that allowed the 
physical exploration and visualization of the different processes of aggregation in 
terms of adhesion, size evolution, and distribution of the peptide; and attenuated 
total reflectance Fourier spectroscopy (ATR/FTIR) which allowed monitoring the 
change of secondary structures for the peptide during the processes studied. It is 
endeavored that this work will help to elucidate the effects attributed to the 
molecular interactions between A! peptide species and antibodies to target Aß 
plaque’s clearance in the brain of AD patients.  Ultimately, this study provides 
novel information critical for the formulation of effective therapies to prevent and 
treat AD with less collateral effects. It also represents a contribution to the basic 
scientific knowledge regarding peptide-antibody interactions with application to 
other diseases related to protein misfolding. 
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CHAPTER 1 
INTRODUCTION AND PREMISES 
 
1.1. Alzheimer’s Disease Facts and Current Therapeutics 
Alzheimer is an irreversible neurodegenerative disease characterized by 
the progressive loss of memory, coordination, social skills, and reasoning.  In 
2006 Alzheimer’s disease (AD) was reported as the sixth leading cause of death 
across all ages in the United States [1, 2].  Furthermore, AD significantly reduces 
the life expectancy and quality of those afflicted by it [3].  Statistics show that 
before a person’s 65th birthday 1 person in every 1000 is diagnosed with AD, and 
after this age this rate increases to 1 person in every 8. The chance raises to 1 
person in every 5 after the age of 80 [4].  
As of today, nearly five million Americans live with AD [5].  This number is 
expected to quadruple in the next four decades [5].  Worldwide AD cases have 
reached 26 million people, and it is expected to increase to 106 million by 2050. 
In addition, reports show that in the United States alone the government and 
affected families spend approximately 148 billion dollars annually to treat patients 
with AD [1, 5].  
 
 
 2 
The onset mechanisms of AD and the cure are still unknown; however, 
three pathological hallmarks are commonly observed among patients with AD: 
the presence of extracellular deposits of amyloid beta (Aß) plaques, intracellular 
neurofibrillary tangles (NFTs), and neuronal apoptosis. Figure 1 (a) and (b) 
shows the first two major microscopic hallmarks mentioned above [6]. 
In this work special attention is rendered to understanding the process of 
Aß plaque formation and clearance.   
Aß peptide deposits (also known as senile plaques) are mainly composed 
of amyloid beta peptides containing 1-40 and 1-42 amino acids residues (Aß1-40 
and Aß1-42 respectively) [7-9]. 
     
Figure 1. Alzheimer’s Disease Hallmarks.  (a) Left: a normal neuron. Right: 
depicting the three hallmarks of AD (Aß plaques, NTF’s, and neuron’s 
apoptosis) [10].  (b) Classical histopathology of AD’s brain showing plaques 
and neurofibrillary tangles (arrows), taken from Cordell, 1994 [11] 
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Despite the fact that Aß peptide does not have a known function in the 
brain, it is present in healthy brains. Studies show that insoluble Aß peptides 
along with a soluble sub-product are proteolytically cleaved from a larger 
transmembrane protein known as amyloid precursor protein (APP) [12, 13].   
Soluble forms of APP are believed to have neuroprotective and 
neurotrophic functions.  However, A! is considered an unwanted by-product of 
the APP processing [4].  The A! peptides are found as globular and non-fibrillar 
forms in small concentrations of pico- to nano-molar and can be traced in the 
extracellular and cytoplasmic (inside the cell) regions in both normal and AD 
brain tissues.  Nevertheless, significantly small oligomeric and protofibril species 
of A! peptides are enough to cause profound cytoskeletal degeneration and cell 
death by plaque formation through underlying mechanisms still not understood 
[14-20].  
It is also known that plaques and tangles are accumulated in neurons, 
mainly throughout the cortical and limbic brain regions [21].  The cortical region is 
responsible for the abilities and activities related to thinking, basic aspects of 
perception, movement, and adaptive response to the outside world.  The limbic 
region is primarily responsible for emotional behavior and the formation of 
memories [22].  
 In the past decade there have been significant advances in the field of AD; 
however, an effective treatment for its cure is not available yet [23].  Currently, 
some common drugs containing active ingredients such as cholinesterase 
 4 
inhibitors1 or glutamine regulators2 are not able to cure the disease.  Rather, 
these drugs only serve to “delay the progression of some of AD’s symptoms” 
[24]. 
There is a tremendous need to find an effective treatment that radically 
stops and prevents the brain’s cognitive degeneration and the irreversible loss of 
memory.  A feasible and promising treatment is immunotherapy.  In the past, 
active immunization (vaccination) was tested in a phase II clinical trial [25, 26], 
which was suspended after observing severe undesired immune response to the 
treatment (7% of the patients out of 312 subjects presented encephalitis). 
Nevertheless, patients monitored afterward showed less cognitive function 
degeneration in comparison to the control individuals, and this study gave 
important insights into immunotherapeutic treatments [26, 27].  
 
 
 
                                            
1 Razadyne® (galantamine) also known as Reminyl®, Aricept® (donepezil), Cognex® 
(tacrine, with safety concerns), and Exelon® (rivastigmine); these are usually prescribed 
to patients with mild to moderate AD, to prevent the cholinesterase’s breakdown. 
 
2 Namenda® (memantine), an N-methyl D-aspartate (NMDA) antagonist; prescribe to 
patients with moderate to severe AD, to regulate production of glutamate (in large 
amounts leads to brain cell death). 
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A possible therapy currently under study is passive immunization, which 
consists of the administration of monoclonal antibodies as a means to assist the 
dissolution and clearance of A! peptide plaques from the brain in patients with 
AD. 
 
1.2. Hypothesis  
It is possible to assess the effects of different monoclonal anti-Aß 
antibodies directed against aggregates of Aß peptides in vitro.  
 
1.3.  Specific Aims and Objectives 
With the purpose of proving the current hypothesis, the work was divided 
into four specific aims, explained below. 
 
1.3.1.  In vitro Assessment of Physicochemical Changes Endured by A!-
Peptide during Aggregation 
 The aggregation process of Aß peptides was first monitored and 
characterized chemically by attenuated total reflection Fourier transform infrared 
spectroscopy (ATR-FTIR); this technique allowed the identification of the 
peptide’s secondary structures involved in such event.  The chemical 
characterization results were then checked by the physical characterization of the 
species encountered at different collection times using atomic force microscopy 
(AFM).   
 6 
 Two isoforms of Aß peptide, Aß1-40 (with 40 amino acid sequences) and 
Aß1-42 (with 42 amino acid sequences), were studied individually and in 
combination (1:1 Aß1-40 to Aß1-42 equimolar mixture, Aß40/42).  The main objective 
was to create a baseline understanding of the kinetic and structural processes 
during fibrillation and to adapt an analytical method for posterior studies. 
 
1.3.2. Analysis and Evaluation of Effects of Monoclonal Antibodies on Aß 
Peptide Fibrils 
The purpose was to determine the effects of antibodies on mature fibrils. 
The antibodies used for this study had different affinity and specificity.  The 
substoichiometric molar ratio of antibody to peptide used in this study was 
1:1000.  
 
1.3.3. Influence of Monoclonal Antibody on the Initial Phase of Fibrillization  
Physical, chemical, and biochemical methods were used to analyze the 
action of different antibodies on Aß peptide species.  This aim focused on 
understanding the extent to which the antibodies were influencing the 
aggregation process and to evaluate the possible effects on plaque clearance, by 
targeting monomers + oligomers, being this the initial phase of aggregation. 
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1.3.4.  Construction and Evaluation of a Biomimetic Cell Membrane as a 
Soft Substrate for Future Studies Involving Peptide-Antibody Interactions 
The main objective was to produce a stable, soft support that could serve 
to mimic the role played by the cell membrane as a substrate for the AD plaques 
and to test the action of monoclonal antibodies on Aß peptide aggregates.    
 
1.4. Contribution of this Work 
The principal contribution of this work was to provide an in vitro method to 
evaluate the effects of antibodies on amyloid beta peptide species, probing their 
effectiveness to destabilize neurotoxic forms of Aß and disrupt their natural 
aggregation pathway.  
This work provided basic scientific knowledge to help understand and 
improve antibody-based therapies for AD, with extension to other protein 
misfolding related diseases.  
 
1.5. Broader Impacts 
The methods and findings from this work opened paths to evaluate critical 
biomolecular interactions to understand protein misfolding related diseases and 
possible therapies.  
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CHAPTER 2 
BACKGROUND 
 
 This chapter gives a general review of concepts and principles that 
provide the bases to later discuss our results and explain the phenomena 
observed during the different studies performed in this work.  
 
2.1.  Amyloid Beta Peptide, Aggregation Process, and Plaque Formation 
The name amyloid comes from the Latin “amylum” and Greek “amylon”, 
meaning starch in both languages.  Rudolf Virchow in 1854 used this name to 
refer to the material deposited in the brain as macroscopic abnormalities, due to 
its reactivity to iodine-sulfuric acid, a reagent used to identify starch and cellulose 
derivatives [28].  It was later in 1859 when Friedreich and Kekule demonstrated 
that the material identified as cellulose was protein [29]. 
Amyloid peptides are not exclusive to Alzheimer’s disease (AD).  They are 
also associated with diseases in other organs such as the liver, spleen, and 
kidney [29].  The amyloid peptide found in neuritic plaques in AD patients is 
known as amyloid beta (A!) peptide due to its natural tendency to form !-sheet 
secondary structures [30].  
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As mentioned in Chapter 1, AD’s neuritic plaques are mainly composed of 
two isoforms of A! peptide, A!1-40 and A!1-42 [31].  These peptides are fragments 
produced by the proteolytic cleavage of a larger transmembrane molecule (APP), 
a process briefly sketched in Figure 2.  The products of this proteolytic cleavage 
are soluble neuroprotective secreted ectodomain sAPP" (via "- secretase 
cleavage) and extracellular A!40/42 peptides (via consequent ! and #-secretase 
cleavage) [32, 33].  It is worth mentioning that even though the concentration of 
secreted Aß1-42 is near 10% of the Aß1-40 concentration, Aß1-42 peptide is the 
main component of neuritic plaques deposits [13, 34]. 
 
Figure 2. Amyloid Beta Peptide Enzymatic Cleavage.  Schematic of Aß1-40 and 
Aß1-42 production by cleavage of the APP proteins by the intervention of 
specialized enzymes 
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The mechanisms of neuritic plaque formation are still unclear. However, it 
has been suggested that soluble species of A! peptide undergo a series of 
molecular rearrangements (misfolding) triggered by environmental stress that 
lead to the formation of fibrillar deposits.   
Under normal conditions, cells with elaborate quality control machinery 
guarantee that proteins folded improperly are eliminated.  This machinery 
includes proteins, specialized organelles and cells that act as chaperones and 
activate processes to selectively eradicate misfolded proteins.  In the case of the 
central nervous system (CNS) the specialized quality control cells are the 
microglial cells.  Proteasomes and lysosomes structures also contribute to the 
degradation and elimination of misfolded proteins inside cells [35].  
However, a particular characteristic that distinguishes amyloid and a few 
other misfolded proteins (such as alpha synuclein, cystatin c and tau among 
others) is the ability to aggregate into higher order species such as oligomers, 
protofibrils, and fibrils.  These species cannot be transported into the central 
catalytic pore of the proteasome enzyme complex for degradation.  This 
characteristic allows amyloid peptides to evade proteasome and lysosome 
quality control machineries, which leads to accumulation of misfolded 
amyloidogenic peptide.  This system grows and propagates, offering resistance 
to degradation for the amyloid toxic [6].  In addition, a small increase in the 
concentration of misfolded protein can dramatically accelerate the process of 
plaque formation [36]. 
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 In vitro amyloid beta peptide fibrillization can be recreated and studied at 
different levels of aggregation by manipulating the peptide’s concentration, 
temperature, pH, and ionic strength of the media [37, 38].  Similarly, it is possible 
to alter and destabilize production of Aß species (oligomers, and protofibrils) 
critical during fibrillogenesis by introducing an external agent (i.e. beta sheet 
breakers).  Although active and passive immunotherapy have shed light into the 
possible mechanism involved in the activation of the immune system and 
clearance of Aß from the brain, little is known about the impact on protein folding 
produced by monoclonal antibodies binding to Aß peptide.  This work evaluates 
the anti-Aß monoclonal antibodies molecules as external agents used to alter 
peptide’s aggregation and promote peptide solubility.   
 
2.2. Amino Acids, Peptide Bond, Peptides, and Levels of Structure 
Amino acids are the building blocks of peptides and polypeptides.  They 
are formed by two main functional groups: an amino and a carboxyl group, which 
are both linked through a chiral central carbon atom (C") that also holds 
hydrogen bonding and a distinctive R group (side chain) as shown in Figure 3.  
The arrangement of these constituents around the central carbon atom makes 
them chiral, meaning they have two isomers, L-isomer and D-isomer.  However, 
the L-isomer is found only in peptides and polypeptides.  Naturally, the amino 
acid residues present in a peptide or polypeptide molecule influence the 
properties and adopted conformations.  
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Figure 3. General Amino Acid’s Structure 
 
 
Peptides and polypeptides are sequential and unbranched polymers of 
amino acids linked from head to tail, with less than 50 and more than 50 amino 
acid residues, respectively [39]. 
The union between a carboxyl group and an amino group through a 
covalent amide linkage is referred to as a peptide bond [35], which is shown in 
Figure 4.  The peptide bond is essentially planar, and it has what is considered a 
double-bond strength that prevents free rotation around it.  However, vibration 
and translation are possible.  In this study, though, only vibration was quantifiable 
with ATR-FTIR spectroscopy; as it will be explained in Chapter 3.  
It is important to mention that the peptide bond is uncharged, and this 
absence of charge allows the amino acid chains to tightly pack together, linked 
by peptide bonds into globular structures [39].  The main event responsible for 
the change in conformation will be the loss or gain of protons depending on the 
media’s pH.  The molecular interactions among peptides are also affected by 
temperature changes and the media’s ionic strength.  
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Figure 4. Amino Acids to Peptide and the Peptide Bond 
 
A final point pertinent to this section is the presentation of the four different 
levels of structure adopted by peptides and polypeptides, which are explained as 
follows. 
 
2.2.1. Primary Structure 
They are simply formed by an amino acid sequence in a linear fashion and 
without taking into account three-dimensional rearrangements of the residues. 
 
2.2.2. Secondary Structure 
They represent a three-dimensional arrangement of the polypeptide in the 
space.  This is conceived by the disposition of the hydrogen bonds between 
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adjacent amino acid residues in a molecule and between molecules, which 
allows the peptide molecules to arrange themselves into characteristic patterns.  
The following were the main secondary structures or patterns investigated in this 
work: parallel ß-sheet, antiparallel ß-sheet, "-helix, unordered (or random coils), 
and ß-turns structures, shown as part of the short peptide in Figure 5.  
 
Figure 5. Peptide’s Secondary Structures  
 
The most important and known secondary structures are the helical and 
pleated segments (formed by parallel or antiparallel ß-strands).  These segments 
constitute regular structures that extend along one dimension.  Most proteins 
exhibit these types of structures, which allow peptides to play specific roles in the 
body.   
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 2.2.3. Tertiary Structure 
This structure is present when polypeptide chains assume a tight three-
dimensional shape, adopting a globular form.  This type of structure gives to the 
polypeptides a lower surface-to-volume ratio allowing the molecules to shield 
from the solvent [35]. 
 
2.2.4. Quaternary Structure 
This structure is composed of several folded peptides or polypeptides that 
are gathered in a more complex molecule, as in the case of enzymes. 
 
2.3.   Antibodies  
Antibodies, also known as immunoglobulins, are natural bioengineered 
proteins with high binding specificity to a wide range of molecules including 
peptides, carbohydrates, and nucleic acids [40].  Figure 6 shows the 
characteristic parts of an antibody molecule.  Antibodies have a particular “Y” 
shape, which is formed by two heavy chains and two light chains.  The type of 
heavy chain determines the antibody isotype (Figure 7) to which they belong. 
The Fab (fragment antigen binding) region of the antibody is composed of 
domains from both heavy and light chains of the antibody, and plays an important 
role in the binding and specificity to a particular site of the antigen known as the 
epitope.  In the case of this work, the antibodies used were specific to Aß 
peptides, either 1-40, 1-42 or both, with epitopes variable depending on the 
antibody.  
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Figure 6. Sketch of an IgG Monoclonal Antibody Molecule. The region of light 
chains is generally recognized as Fab and promotes specific biding 
characteristics 
 
The distinction between the different antibody isotypes is based on their 
heavy chain, which in turn is related to the source where they are produced; for 
instance, IgA is found in the mucous secretions, while the IgG is mainly found in 
the blood and in tissue liquids.  A functional difference between the various 
isotypes is based on the part of the immunoresponse’s cascade of which they 
are part.  Between the 5 main isotypes shown in Figure 6 (IgG, IgA, IgE, IgD, and 
IgM), the most common isotype in the human body is the IgG, which was also 
used in this work. 
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Figure 7. Heavy Chain Isotypes of Mammalian Antibodies.  IgG provides the 
majority of antibody-based immunity against invading pathogens 
 
In general, antibodies that are synthetically produced can be classified in 
two large groups: monoclonal and polyclonal.  Polyclonal antibodies are obtained 
from the sera of immunized animals, and they are a mixture of different 
immunoglobulin types binding to multiple sites on the antigen used for 
immunization [41].  On the other hand, monoclonal antibodies have a single 
immunoglobulin type binding to a single specific site of a molecule (antigen, 
protein, carbohydrate or nucleic acid) used for immunization.  
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Figure 8. Monoclonal Antibody Production Diagram  
 
Monoclonal antibodies are synthetically produced by the fusion of 
antibody-producing mouse B cells, which have a finite life span, with 
“immortalized” cells of a mouse myeloma (cancer cells).  These fused cells are 
cultivated and successful immortalized antibody producing cells are selected 
[41].  This process is pictured in Figure 8.  Each cell or clone obtained by this 
method is capable of producing large amounts of a single type of antibody, which 
binds to specific epitopes of the antigen molecule (Aß1-40, Aß1-42 or both).  
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2.4. Immunotherapy Preceding Work  
Immunotherapy for treating AD is a subject that has been investigated 
since the late 1990’s.  Beka Solomon (1996) and her group were the first who 
reported the effectiveness of N-terminus antibodies to block fibril formation in 
vitro [42].  After this publication, many other studies involving immunotherapy for 
AD were published from Solomon’s group and from other scientists all over the 
world [43].  
In 2003, preliminary results were published of the first clinical trial (Elan-
Wyeth clinical trial) [44]  in  which  patients  with  AD  where  vaccinated  with 
AN-1792  (purified Aß1-42), and after advancing to a Phase II (372 patients with 
mild to moderated AD), the study was stopped after finding 7% of the patients 
suffering from encephalitis.  Nevertheless, the immunized patients were 
monitored after the treatment was stopped and a reduction in cognitive decline in 
comparison to the controls was found.  This has been the basis to continue in the 
search for an effective but safe immunotherapy treatment for patients with AD 
[45].  
It is important to note that immunotherapy can be classified in two types: 
active and passive immunization (Figure 9).  Briefly, active immunization can 
take place either by injecting into the individual the whole antigen or part of it, 
whichever way provokes an immune response resulting in the production of 
specific antibodies to the injected antigen.  The other type of immunization 
consists of the injection of specific antibodies directed to the antigen of interest 
(either monoclonal or polyclonal).   
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Figure 9. Active vs. Passive Immunization. Adapted from Schenk, 2002 [27] 
 
An ideal scenario for using immunotherapy to target a specific event 
(clearance of Aß deposits) would be decreasing the body’s immune response to 
a mild level, so that the external agent (antibody in the case of passive 
immunization) could mediate the desired event in a controlled manner.  From 
here derives the idea of using monoclonal antibodies to trigger the clearance of 
Aß deposits.  
Indeed, this idea has been tested in mice, finding activation of the clearing 
plaque mechanisms and cognitive recovery to a certain level [46-54].  But still the 
key questions remain: What is the mechanism involved in this clearing event? Is 
it possible to determine what antibody will activate and help the body to clear 
these deposits in the most effective way? What about the quantities? 
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The present study provides insights that help to understand, from a 
molecular interaction point of view, the effect of the antibody on the plaques and 
help to identify the species at different stages of the plaques formation and 
clearance. 
 
2.5. Antibodies - Peptides Interactions Theories 
For the purpose of this study it is important to consider the affinity between 
the antibody and the A! peptide from a thermodynamic point of view.  The affinity 
is related to the type of interactions that occur at the interface between the two 
molecules.  In terms of energy, the affinity between two molecules will depend on 
two thermodynamic factors, the enthalpy and entropy at the interface [55].  
When antibodies and A! peptide molecules are free in aqueous solution, 
they have a considerable configurational (translation and rotational energy, 
measurable with ATR-FTIR spectroscopy) entropy that is lost when the 
association (binding) occurs.  This effect is observed in the analysis to be 
presented in Chapters 4 to 6.  
Moreover, the noncovalent interactions (H-bonds, salt-bridges and van der 
Waals forces) between each molecule’s surface residues with the water are lost 
when the antibody and Aß peptide enter in contact.  Nevertheless, when the 
bound water is released from the two interacting interfaces, it leads to an 
increase in entropy of the solvent.  Hydrophobic residues that become buried at 
the interface cause an increase in entropy of the solvent in a similar way. 
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However, at the same time, new hydrogen bonds, salt bridges, and van der 
Waals interactions are formed between the antibody and the A! peptide [40, 56].  
Energy losses and gains due to molecular interactions driving aggregation 
can be indirectly detected as a function of integrated absorbance with ATR-FTIR 
spectrometric analysis.   
In addition, there are other factors that might also affect the molecular 
interactions between the antibody and the A! peptide such as the presence of 
salts (ions in solution) and the posttranslational modifications involving 
morphological changes, as is the case of monomers, oligomers and fibrils 
species adopted by the A! peptide [57]. 
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CHAPTER 3 
ANALYTICAL TECHNIQUES AND MATERIALS 
 
 In this study, different analytical methods are combined to provide a 
comprehensive physicochemical characterization and explanation of the 
processes of peptide aggregation, as well as the effects produced by different 
anti-Aß monoclonal antibodies when they are tested against Aß peptide 
aggregates.  This chapter explains the techniques used in a systematic way by 
dividing them into physical, biochemical and chemical characterization.  The 
techniques explained here are brought into play in the subsequent chapters. 
 
3.1. Physical Characterization 
These techniques served to evaluate the morphology of the samples by 
studying their dimensions as well as dispersion and distribution of the different 
peptide aggregates across the substrate’s deposition area.  
Two physical characterization techniques were utilized: transmission 
electron microscopy (TEM) and atomic force microscopy (AFM).  The primary 
aggregates of interest for the study were monomers, oligomers or protofibrils, 
and fibrils.  
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3.1.1. Transmission Electron Microscopy (TEM) 
 This is a microscopy technique that consists of a focused beam of 
primary electrons that is directed through the sample under study.  The electron 
beam can be generated by thermionic 
emission from a filament, commonly 
tungsten.  However, the electron’s beam 
can also be produced by a lanthanum 
hexaboride (LaB6) source.  The electrons 
are accelerated using electrostatic and 
electromagnetic fields to focus the beam 
and deflect it to a constant angle [58].  
The instrument used was a 
Morgagni-268D transmission electron 
microscope from FEI Corporation (NE, 
US), which is shown in Figure 10.  The 
source of primary electrons in this 
instrument comes from the thermionic 
emission of a tungsten filament.  The 
instrument provides a point-to-point 
resolution of 0.45 nm and a resolution between lines of 0.34 nm.  It has a Soft 
Imaging Mega 3 digital camera with an ultimate resolution of 1280x1024 pixels 
per image.  All processes of the specimen’s imaging takes place in a vacuum 
chamber (10-6 Torr). 
 
 
Figure 10. Transmission Electron 
Microscope  
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The accelerating voltage chosen for the analysis was either 100kV or 
60kV depending on the thickness of the sample, and it was adjusted to get the 
best contrast.  
The sample preparation depends on the specimen to be studied.  For 
instance, in the case of amyloid peptide, a drop (5 #L) of the sample is simply 
placed on a special grid (rinsed with 5 #L of Millipore water) and dried with 
ultrapure nitrogen.  
In this study two different types of grids were used: Formvar coated grid 
stabilized with evaporated carbon film (150 mesh, FCF150-Cu) and inert silicon 
nitride grids (DuraSiNTM).  The last one used to characterize the sample not only 
with TEM but also with AFM.  Both grids were purchased from Electron 
Microscopy Science (PA, US), and they are shown in Figure 11 below.  
 
       
 
 
 
 
  
                  (a) Formvar/Carbon                        (b)  DuraSiNTM 
                       (150 mesh) 
Figure 11. TEM Grids Used in this Work.  (a) Carbon grid (150 mesh) coated 
with Formvar film, a transparent and inert polymer.  (b) DuraSiNTM, showing 
window covered with silicon nitrate 
 Diameter =3.05mm 
Window    
0.5x0.5-mm x-y 
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3.1.2. Atomic Force Microscopy (AFM) 
This technique is also known as scanning force microscopy (SFM) or 
scanning probe microscopy (SPM).  It allows for the visualization of the 
topographical structure of conductive and non-conductive materials.  Commonly, 
an AFM consists of a piezoelectric scanner, on which the sample rests; this 
scanner allows movements in a precise fashion in the x, y, and z directions.  
However, having the three-dimensional movement freedom in the same scanner 
makes the instrument very sensitive to disturbances, resulting in long collection 
times.  
In this work, the AFM used (XE-100, Park Systems Inc., CA, US) consists 
of two piezoelectric scanners; one scanner accounts for the x-y movements only, 
and another piezoelectric scanner, located on the head where the cantilever 
rests (Figure 12(a)), separately allows movement on the z direction.  This new 
design increases imaging flexibility and reduces the collection time.  Another 
important component in the AFM is a photodiode, which senses the movements 
of the scanning tip when a laser positioned on it deflects due to its interaction 
with the sample.  This deflection is then translated by the photodiode into either a 
current or a voltage, and ultimately into a digital image (Figure 12(b)).  
With AFM, it is possible to image and characterize samples on a solid-gas 
interface as well as solid-liquid interface.  In this work images were collected in 
both edia; however, primarily images were collected on solid-gas interfaces. 
Atomic force microscopy allows characterization of the sample’s surface 
by three different modes, as explained below. 
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3.1.2.1. Contact Mode 
In which the tip of the cantilever gets in touch with the sample (hard 
materials). 
 
3.1.2.2. Non-Contact Mode 
Where the tip does not contact the sample.  The non-contact mode is 
used in characterization of soft materials (biological, i.e. cells). 
 
                     
       (a)  AFM,  XE-100 Schematic                  (b)  Imaging Process 
  
Figure 12. AFM and Scanning Process.  The sample’s topology can be 
studied by dragging a micro-scale cantilever across its surface. (a) Shows a 
full diagram of the instrument; (b) illustrates a detail of the cantilever and 
detection system on A! fibrils 
 
3.1.2.3. Intermittent or Tapping Mode 
This mode can be used to prevent the cantilever from being trapped by 
capillary forces caused by the presence of an extremely thin film of water 
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surrounding the sample in air.  Also this mode is use to preserve the sample, 
especially when biological samples are analyzed. Tapping mode was used to 
analyze the Aß peptides deposited on mica.  
Therefore, in this study tapping was the mode of preference for the 
samples’ characterization.  During the tapping mode, the cantilever is deliberately 
excited by an electrical oscillator to amplitudes of up to approximately 100 nm, 
creating an effective tapping modality as the cantilever travels over the sample 
(Figure 12(b)).  In addition, because the contact time of the tip with the sample is 
relatively short, it is possible to reduce lateral force (that could cause distortion of 
the image) and also preserve the sample’s morphology [59].  
 There are a wide variety of cantilevers commercially available; the 
selection depends on the application and media. In this work, the cantilever used 
was the type Tap300Al (Budget Sensors, Bulgaria).  These cantilevers were 
purchased with an aluminum coating to increase the laser’s reflectivity. This type 
of cantilever has a resonant frequency of  300 ± 100  kHz and a force constant of 
40 N/m.  
 The substrate material used to image the peptide’s samples was mica.  
This is a preferred material when working with biological specimens [59].  Mica 
was selected because it is atomically smooth (0.2 to 0.6 Å), and at the same 
time, an easy to clean (sheets cleavage) and inert material. In this study natural 
mica of the type ASTM V-1, purchased from Axim Mica (NY, US), was used.  
The physical characterization methods used in this study facilitated 
checking the physical size of the aggregates during time and determining the 
 29 
kind of secondary structures dominating at each stage of the aggregation 
process of samples with anti-Aß monoclonal antibodies and alone. 
 
3.1.2.4. General Protocol of Sample Deposition and Data Analysis 
In this work all the samples were deposited under a laminar flow cabinet 
(Class 100) to avoid contamination by settling of undesirable particles.  
Each aliquot collected at specific times was diluted with Millipore water to 
20 #M.  Then, 5 µL of the diluted solution was deposited on freshly cleaved mica 
and incubated for 5 min.  A small Teflon O-ring (external $ 7mm, internal $ 
5mm) placed on the mica served to confine the peptide solutions.  The excess of 
peptide solution was flushed with 1 ml of Millipore water, dried with ultrapure 
nitrogen, and stored in a vacuum dessicator at 30 in Hg for later AFM imaging.  
As mentioned in Section 3.1.2, the images were taken with a XE-100 
atomic force microscope from Park Systems Corp. (Santa Clara, CA) at 25°C. 
The scans were performed with TAP300Al cantilevers (Budget Sensors, 
Bulgaria) using tapping mode, to preserve the sample.  The image resolution was 
512x512 pixels, and the scan rate was 0.75 Hz, the set point of the cantilever 
was variably moved to satisfy the image quality but never lowered beyond -0.260 
#m. Images were collected at 5 random points on the mica surface, and each 
point was imaged using three different scan sizes, first 35x35-#m x-y, then 
zooming to 10x10-#m x-y, and finally to 2x2-#m x-y; this was done to assure a 
fair exploration of the sample distribution across the mica.  
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The processing and analysis of the images was performed with WSxM 
software (version 5.0) [60].   
 
3.2. Biochemical Characterization 
 
3.2.1. Aß Soluble Species Detection: SDS-PAGE and Immunoblotting 
The combination of these two methods, SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis) and Western Immunoblotting allow for 
discriminating the different soluble peptide species in the incubation solution 
when separated by their difference in  molecular weight.  
In this sense, the sample, after being diluted in water and centrifuged, is 
first analyzed with SDS-PAGE, in which the peptide is loaded on a 4-12% Bis-
Tris gel, and then exposed to an electrical current that allows the diverse 
aggregates species to migrate and distribute on the gel at different speeds, 
depending on their molecular weight. Normally, the gel used is polyacryamide.  
This is an inert material, and serves only as a medium for the peptides to move 
(under buffered conditions). 
The peptide’s species recognition takes place once the peptide 
(distributed on the gel) is carefully transferred to a polyvinylidene difluoride 
membrane where it is likely to bind.  A step prior to recognition is the “blocking” 
step, in which either Bovine serum albumin (BSA) or non-fat dry milk are used to 
prevent the interaction of the antibody with the unbounded sites of the 
membrane, and therefore creates “noise”.  
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The membrane is incubated with a primary antibody specific to N-terminal 
of the peptide (Aß) by gentle agitation for 12 hours. Then, the gel is rinsed to 
remove any unbounded primary antibody, and at this point, a second antibody 
that targets the primary antibody is added to enhance recognition.  
Finally, the immunostained peptides can be visualized using 
chemiluminescence techniques.  For the effect of this work, this step was 
performed in accordance with the manufacturer’s recommendations (ECL, 
Amersham, Denmark).  Western blots images were captured with a Fujifilm Lass 
300 Intelligent dark box scanner and quantified with a linear range of detection 
using Alpha Ease software (AlphaEaseFC, Alpha Innotech Corporation, San 
Leandro, CA).  This analysis allows one to quantify the intensity of the bands 
corresponding to the following: monomers species (4.5 KDa), Low Molecular 
Weight (LMW) oligomers or protofibrils (14 to 21 KDa), High Molecular Weight 
(HMW) oligomers or protofibrils (38 to 98 KDa), and larger soluble aggregates 
(188 to 250 KDa).  Figure 13 shows the schematic representation of the analysis 
explained above. 
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Figure 13. SDS-PAGE and Western Blot Schematic. It shows the steps 
involved in the biochemical characterization of A! aggregates.  The sample is 
diluted and centrifuged, then exposed to an electrical current through a gel 
separating aggregates by molecular weight, then the aggregates are 
transferred to a membrane and immunotagged.  The membrane is digitized 
and the results are quantified with computer software 
 
It is important to mention that during the peptide aggregation, monomers 
associate as a paranuclei species (pseudostable) at the initial times of incubation 
[61].  This paranuclei can be detected from the monomeric through the LMW 
region.  In the next chapter, this technique is linked to the physical view of the 
different species and is also investigated with atomic force microscopy. 
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3.3. Chemical Characterization 
Vibrational spectroscopy was used in this work to analyze and monitor the 
chemical configuration changes of amyloid peptides.  This technique also 
allowed to determine and understand the effects of antibody molecules targeting 
Aß peptide.  While the experimental setup is relatively simple, the analysis of the 
resulting data is rather complex.  Hence, this section explains the most important 
details to be considered for the analysis and further understanding of the results. 
 
3.3.1. Attenuated Total Reflection - Fourier Transform Infrared 
Spectroscopy (ATR-FTIR) 
 
3.3.1.1. Principles 
This technique is based on the combination of two main principles: the first 
one is the detection of the vibrational energy emitted by the molecules when 
excited by an infrared (IR) light; and the second principle is based on enhancing 
the interaction between the molecules analyzed and the  IR beam, therefore 
improving the detection sensitivity of the method.  The last principle, occurs by 
using a crystal with high refractive index that allows the IR beam to undergo 
multiple internal bouncing when entering the crystal in a 45° angle of incidence, 
the beam creates an evanescent field at each point of contact with the sample’s 
interface (Figure 14).  The evanescent field created by the beam, approximately 
penetrates the sample 1.66 #m in depth; distance measured at 1000 cm-1 for a 
ZnSe crystal.  This depth of penetration varies with the crystal used (ZnSe, Ge, 
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diamond, etc), angle of incidence, and refractive index of the sample.  In this 
work all the experiments were performed using a ZnSe crystal as the ATR 
element. 
 
 
Bending 
 
 
 
Stretching 
 
 
 
 
 
Enhancement of the signal with an ATR crystal. The 
evanescent field penetrates the sample 1.66 !m 
approximately for a ZnSe Crystal  
 
       (a)                                                          (b) 
Figure 14.  ATR-FTIR Spectroscopy Principles.  (a) Two main and general 
vibrational energies.  (b) Schematic representation of an ATR accessory, 
where the main element is a ZnSe crystal used to enhance the sensitivity of 
detection.  The crystal is beveled in the two edges where the beam enters and 
exists in the crystal, allowing 12 points of contact with the sample.  The 
equation explains the depth of penetration that the beam has inside the media 
under study, which depends on the wavelength of the energy, the angle of 
incidence on the crystal, and the refractive index of both the sample and 
crystal 
 
The enhancement of the detection is of particular importance for this study 
in which the concentration used is relatively small (100 #M).  
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It is important to mention that ATR-FTIR spectroscopy works in the Mid-
Infrared region of the electromagnetic spectrum (Figure 15), going from 400 
through 4000 wavenumbers.   
 
 
Figure 15. Electromagnetic Spectrum.  The Mid-IR region is located between 
400 and 4000 wavenumbers  
 
The range can be slightly modified by the ATR crystal used.  For instance, 
in the case of ZnSe crystal the range goes from 650 to 4000 wavenumbers. 
 
3.3.1.2. Peptides and Amide Vibration Modes 
As explained in Chapter 2 section 2.2, amino acid residues formed the 
peptides. The functional group of amino acids is the amide group, -C(=O)NH-.  
Therefore, central vibrational energy characteristic of the peptides is the amide 
type [6, 62, 63].  The Mid-IR region of the electromagnetic spectrum shows 5 
regions correspond to the amide groups (Figure 16(a)). 
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Figure 16. Amide Bands.  Showing the mid-IR range going from higher 
vibrational energy to lower: (a) All the amide bands encountered in the mid-IR 
range, (b) Amide I, the most straightforward band holding the secondary 
structure information of the peptide, (c) NH stretching and bending energies 
are shown (NH stretching also is present in the Amides A and B). Amide II can 
be related to protein absorption to the crystal, (d) Amide III region.  The 
example spectrum shown here corresponds to 5 days of incubation Aß40/42 
Peptide  
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From the amide bands or regions shown in Figure 16 the more relevant 
are the amide I and amide II regions; ranging from 1600 to 1700 cm-1 and 1500 
to 1600 cm-1 respectively.  The amide I region, reveals the changes suffered by 
the backbone of the peptide without neglecting the side group’s effects [64].  
Because, interactions of the type NH and NH2 allow the peptide to anchor to the 
crystal’s surface and this interactions are detected in the amide II region, this 
interactions serve to investigate and understand the process of peptide’s surface 
adsorption and desorption; simply by calculating the area under the amide II 
region. 
The amide I region is analyzed by its deconvolution in different peaks, 
each corresponding to an existing secondary structures of the peptide.  Table 1 
summarizes  approximately the ranges in which the secondary structures of 
amyloid peptides are localized.  
The amide I band is sensitive to the secondary structure change in peptide 
and polypeptides [62].  However, explaining the large splitting into two bands of 
antiparallel ß-strands structures, has become a challenge for researchers. In this 
sense, some light on this issue has been shown by the use of the transition 
dipole coupling mechanism theory [65].  This mechanism serves to explain how 
the Aß structures split in two bands, one positioned with center at 1630 cm-1 and 
the other center at 1690 cm-1.  Other effect such as hydrogen bonding also 
modifies the amide I frequency of the polypeptide. 
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Table 1. Peak Assignment of Aß Secondary Structures.  The assigned peaks 
have been selected by gathering data from related literature [66, 67] and adapted 
from the current study observations during secondary structure study 
Structure Range [cm-1] 
Antiparallel ß-Strands 
      Low frequency, Intermolecular  
      High frequency, Intramolecular 
 
1597-1630 
1680-1710 
Parallel ß-Sheets 1628-1640 
Unordered  1640-1651 
"-Helix 1650-1657 
ß-Turns 
      Low frequency, Intermolecular 
      High frequency, Intramolecular 
 
1657-1675 
1680-1700 
 
3.3.1.3.  Hydrogen Bonding  
The nature of hydrogen bonding has an evident effect on shifting the 
position of peaks for different structures [68] as explained below. 
The peak absorbance for structures in the amide I region correlates to the 
strength of the hydrogen bonding; this is true for most cases except in the case 
of the main frequency band of !-sheets.  In descending order of hydrogen 
bonding, the secondary structure bands are the following: intramolecular 
antiparallel ß-strands extended chains (1610-1628 cm-1), intermolecular ß-sheets 
(1630-1640 cm-1), "-helices (1648-1658 cm-1), 310-helices (1660-1666 cm-1) and 
non hydrogen bonded amide groups in DMSO  (1660-1665 cm-1) [69].  This 
range is slightly varied from those shown in Table 1.  However, at the moment of 
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the analysis both are considered.  The peak frequency of the amide I group is 
lowered by 20 to 25 cm-1 and is influenced by the two possible hydrogen bonds 
connecting to the C=0 group. 
In the case of polypeptides, experiments indicate that amide I main 
absorption band can vary by 30 cm-1 because of different hydrogen bond 
strengths among peptide residues. 
Alpha-helices hydrogen bonding to solvent influences absorption frequency  
by  approximately 20 cm-1; solvated  "-helices  induce a 20 cm-1 lower 
absorbance maximum for amide I. 
 
3.3.1.4.  Transition Dipole Coupling Mechanism (TDC) 
 It is a resonant mechanism that causes secondary structures to influence 
amide I absorbance frequencies.  Transition Dipole Coupling (TDC) is dependent 
on distance between amide groups in a peptide chain, and it is caused by 
resonance interaction due to oscillation of dipoles of such neighboring amide 
groups.  TDC manifests itself in two ways on the FTIR spectra [70, 71] and is 
explained as follows. 
 
3.3.1.4.1. Exciton Transfer 
In an analogous way to fluorescence (Förster) resonance energy transfer 
(FRET), energy is absorbed and transmitted to nearby structures delocalizing 
excitation states over a length of 8 Å; typically exciton transfer energy for "-helix 
has a constant of 0.5 ps (pico seconds).  
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3.3.1.4.2. Exciton Splitting 
Additionally, TDC results in the splitting of bands since coupled oscillators 
result in different excitation energy levels in phase and out of phase. This, results 
in the splitting of the absorbent contribution on amide I for the case of antiparallel 
!-sheet structures, with an approximately separation of 70 cm-1. 
 
3.3.1.5. General ATR-FTIR Data Analysis Protocol 
Each spectrum collected with ATR-FTIR spectroscopy was smoothed and 
baseline corrected in Omnic (version 7.2a, Thermo Fisher Scientific).  The 
spectroscopical regions of interest were the amide I (1600-1700 cm-1) and amide 
II region (1500-1600 cm-1).  To the amide II region the area under the curve was 
simply calculated and this value represented the absorption or desorption of the 
peptide to or from the crystal respectively.  
The amide I region (1597-1710cm-1) was selected and saved in Comma 
Separated Values (CSV) format.  The file was then analyzed with OriginPro 
(version 8 SR5, OriginLab). In OriginPro the analysis was perfomed by peak 
fitting using the parameters shown in Table 2.  This operation is known as 
spectrum’s deconvolution by interactive least-squares curve-fitting technique, 
using a Gaussian distribution model. 
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Table 2.  Fitting Parameters and Boundary Conditions 
N° Meaning Value LB Value LB Param UB UB Value 
0 offset 0   y0   
1 center 1614.8125 1597 <= xc_1 <= 1630 
1 width 8 1 <= w_1 <= 8 
1 amplitude 0.0097 0 <= A_1   
2 center 1628 1628 <= xc_2 <= 1640 
2 width 8 1 <= w_2 <= 8 
2 amplitude 0.01229 0 <= A_2   
3 center 1640 1640 <= xc_3 <= 1651 
3 width 6.11721 1 <= w_3 <= 8 
3 amplitude 0.00483 0 <= A_3   
4 center 1651.05348 1650 <= xc_4 <= 1657 
4 width 6.35162 1 <= w_4 <= 8 
4 amplitude 0.0033 0 <= A_4   
5 center 1664.41119 1657 <= xc_5 <= 1675 
5 width 6.93525 1 <= w_5 <= 8 
5 amplitude 0.00224 0 <= A_5   
6 center 1676.44412 1670 <= xc_6 <= 1690 
6 width 7.39482 1 <= w_6 <= 8 
6 amplitude 0.001 0 <= A_6   
7 center 1685.63946 1680 <= xc_7 <= 1710 
7 width 5.59086 1 <= w_7 <= 8 
7 amplitude 5.19289E-4 0 <= A_7   
 
The resulting peaks after the curve fitting represent the contribution of 
each secondary structure, this quantity is calculated by determine the area under 
each fitted peak, and consequently the addition of these peaks represent the 
amide I region.  Each peak is assigned as a particular structure depending on the 
position. In this way it is possible to monitor the secondary structure percentage 
(as a normalized value) and the raw value.  The latest value can be related to the 
kinetic of each particular secondary structure followed with time. An example of 
this fitting is shown in Figure 17. 
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Figure 17. Sample’s ATR-FTIR Data Analysis. It Depicts A!1-42 after 48 hours 
of incubation. The colored areas correspond to the estimated contribution of 
each specific structure to the total absorbance calculated by deconvolution of 
the amide I region. Also the amide II region is shown and it represents the 
surface protein adsorption  
 
It is important to mention, that in previous studies (Jimenez, 2005 [72]) the 
investigation of the amide I has been performed considering the band 
assignment in a more general fashion. Assuming only one frequency of 
antiparallel ß-sheets (called intermolecular interactions, 1610-1625) and 
considering the high frequency range (1670-1700 cm-1) as ß-turns.  In this new 
study to give to the antiparallel ß-sheets structure the importance they have and 
to understand the role they play during aggregation/dissolution of the peptide the 
bands assignment in the amide I region has been judiciously modified assigning 
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ß-turn to a range of 1670-1690cm-1 and a introducing a new band between 1680-
1710cm-1 corresponding to high frequency antiparallel ß-sheets [73, 74]. 
 
3.3.1.6. Some Relevant Consideration for the ATR-FTIR Analysis 
In order to understand the possible molecular interactions taking place in a 
solution and related to the absorption energies present at determined points of 
the spectra, it is important to consider the following important phenomena. 
 
3.3.1.6.1. Protonation or Deprotonation 
For instance, at pH 7.4 the Aß1-40 and Aß1-42 are deprotonated (see 
Appendix A), having a net charge (theoretically) of -2 and -3 respectively. This 
unbalance of net charge contributes to the conformational change of the peptide 
molecules as well as their absorption energies.  
 
3.3.1.6.2. Chemical Properties of Neighboring Groups 
For instance amide group, allows for localizing a particular absorption 
band and differentiating it from a C=O originated from an aldehyde or ketone 
group. In this work this is not relevant because it is known that only peptides 
would be showing this C=O bonding.  
 
3.3.1.6.3. Bond Angles and Conformations 
Under the effect of Coulomb interactions, proteins modify their bonding 
angles; this affects the three-dimensional structure of their backbone originating 
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changes (conformational changes). This combination is responsible for the amide 
I band sensitivity to secondary structure. 
 
3.3.1.6.4. Hydrogen Bonding 
Another important interaction encountered in peptides is the hydrogen 
bonding; this type of interaction stabilizes the peptide molecules in their lower 
energy state depending on the media conditions. The strength of hydrogen 
bonding can be directly observed as mentioned earlier in section 3.3.1.3.  
 
3.3.1.6.5. Conformational Freedom 
A very important aspect of FTIR spectroscopy is the fact that as structures 
are more flexible, the band that they represent in the vibrational spectrum is 
wider. Heterogeneity of structures caused by conformational freedom results in 
broader spectrum bands defining structures. On the other hand, more rigid 
structures have less conformational freedom and result in tighter spectrum 
bands. When structures interact through binding, conformational freedom is 
usually reduced; this is also the case for molecules binding peptides and proteins 
and for peptide-peptide binding, resulting in the reduction of bandwidth by a 
factor of two [75].  The incremented rigidity and reduced conformational freedom 
sometimes increases rigidity in distant parts of large molecules such as proteins 
as well.  
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3.3.1.6.6. Overlap of Conformational Changes in the Spectrum  
The fact that different structures overlap in the spectrum makes analysis 
of signals more complex. However, spectra can be subtracted, with the limitation 
that the infrared difference spectrum reveals only the net change of secondary 
structure. In this work, by amide I deconvolution it is possible to distinguish the 
structures during overlapping of conformational changes. 
 
3.3.1.6.7. Rigid Domain Movement  
Movements of relative large structures are not detected in near infrared 
spectra. Hinge regions of proteins are an interesting example in which the larger 
rigid domains are not detected while the hinge flexible region is prevalent in the 
spectra. An example of two rigid domains moving about a flexible domain is 
shown in Figure 18 (black line). In this case, the detection of the flexible domain 
would be prevalent, established by comparing it to the larger and more rigid 
domains attached to it. The detection would be limited to the conformation of the 
relative orientation of neighboring amide groups in the flexible domain.  
However, there is increased sensitivity in the detection of conformational 
changes where the backbone portion of a molecule is intimately linked to flexible 
domains; for example, if an "-helix shortens, there are changes not only in the 
amide modes of the unwinding backbone portion, but also in others amides 
related to the remaining portion of the helix. 
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3.3.1.6.8. Subtle Changes within Secondary Structures  
Finally, subtle changes within secondary structures, such as twists in ß-
sheet, bending of an "-helix, or hydrogen bonding to backbone carbons, are 
detectable in the amide I of the mid-infrared spectrum. 
 
 
Figure 18.  IR Spectrum Analysis and Rigid Domain Movement. 
Adapted from Barth 2007 [76] 
 
3.3.1.7. General Experimental Methodology  
The experiments were performed with a 6700 Nicolet spectrometer 
(Thermo Fisher Scientific, US). Two different accessories were used: an ATR 
trough plate for the study of monomeric solutions (with more flexibility to 
evaporate and redissolve the peptide’s in different solvents), and a closed ATR 
flow cell accessory for the peptide solution in HFIP, and the oligomeric and 
fibrillar solutions (hermetically closed to avoid evaporation during long incubation 
times, and with temperature controller).  
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The IR beam was focused at normal incidence onto one of the 45° 
beveled faces of the ATR zinc selenide (ZnSe, ns = 2.4) trapezoidal crystal, 
where the IR beam undergoes multiple internal reflections resulting in signal 
enhancement. A crystal made of ZnSe was the preferable used because of its 
low reflection losses in the infrared [77], wide infrared range (between 20,000 
and 650 cm-1), compatibility to aqueous solutions, and chemical inertness    
(Appendix B).  
After each measurement, the flow cell was dismantled and thoroughly 
cleaned with isopropyl and Millipore water; in addition the crystal was exposed 5 
minutes to UV to eliminate organics, and rinsed again with Millipore water. All the 
flow cell parts were finally dried with an ultrapure nitrogen stream and re-
assembled. 
 
3.3.1.8. General Data Analysis 
For the cases of long incubation times (i.e., 24h, 48h, or longer) and with 
several spectra collected by hour (i.e., 6 spectra per hour), high variability is 
recorded from spectrum to spectrum.  For these cases, set of spectra with time 
ranges of 4 hours were averaged and the variance among them was calculated.  
To calculate the average absorbance (Eq.1) for a time frame (for example 
4 to 8 hours), all curves under that timeframe are added and averaged by the 
number of curves recorded during that time; this yields an average spectrum: 
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! 
Average Absorbance(w) =
Absorbance(t) 
t1
tn
"
n
 
 
(Eq. 1) 
 
The software calculates then the variance for the curves during that time 
frame as Eq.2 shows: 
  
! 
Variance(w) =
Absorbance(t) " Average Absorbance( )2 
t1
tn
#
n
 
 
(Eq. 2) 
 
Finally, the number to calculate the Relative Spectral Variance (Eq.3), the 
variances (Eq.2) for each wavelength in the region are integrated to calculate the 
area under the variance curve, divided by the average absorbance (Eq.1), and 
multiplied by 100.  
  
! 
Relative Spectral Variance =
Variance(w).dw
w1
wn
"
Average Absorbance(w).dw
w1
wn
"
*100 
 
 
 
 
 
 
 (Eq. 3) 
 
  
This relative spectral variance or %Variance is a good indicator of stability 
of the processes undergone by Aß peptides in their stabilization at different 
conformations; typical values for stable Amide I and Amide II regions are around 
10%; as shown in Figure 30.  
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3.4. Reagents  
 Table 3 lists all reagents used in this work. 
Table 3. Reagents Used in this Work 
Reagent Manufacturer  Description 
1,1,1,3,3,3-Hexafluro-2- 
Propanol (pa: >99%), 
HFIP 
Fisher Sci. Very volatile transparent liquid  
Methyl Sulfoxide 
Anhydrous (p:>99%), 
DMSO or Me2SO 
Acros Viscous transparent liquid 
Tris (Crystallized) 
p:>99%) 
Fisher Sci. 
BP152-500 
White powder 
Phosphate-buffered 
saline, PBS 
Sigma-
Aldrich, 
P3813 
White powder  
Hydrochloric Acid, HCl Acros  
124630010 
 
Nitrogen  Airgas 
NI UHP300, 
Ultrapure gas 
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CHAPTER 4 
AGGREGATION PATHWAYS OF AMYLOID BETA PEPTIDE  
 
Amyloid beta (Aß) peptides and proteins in general modify their molecular 
configuration (i.e., secondary structures) influenced by the media conditions in 
order to minimize their overall energetic state [78, 79].  This chapter will analyze 
and discuss how media conditions affect the secondary structure of Aß peptides.  
The conditions evaluated here have been used to identify features corresponding 
to each Aß species during aggregation.  The species studied are: monomers, 
which are the single molecules of Aß peptide characterized by their hydrophobic 
character (Aß1-42 in particular); oligomers, which are found during the nucleation 
or seeding state and that are also known as the intermediate species during 
fibrillization [80]; and finally the fibrils, the main components of neuritic plaques in 
Alzheimer’s disease brain tissue. In later chapters the findings from this chapter 
will be used as guidelines to elucidate changes in aggregation and effects of 
antibodies on the Aß peptide species.  
 
4.1.  Protocols and Methods 
 Each peptide in this study, Aß1-40, Aß1-42, and their equimolar mixture 
Aß40/42, were prepared following a common protocol explained below.  
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4.1.1. Peptide’s Homogenization  
Amyloid Beta (Aß) peptides were purchased from American Peptide INC. 
(Sunnyvale, CA).  Table 4 below shows the general specifications of Aß peptides 
used in this study.  
The peptides were homogenized and aliquoted in HFIP, as described by 
Stine et al. 2003 [37].  Briefly, HFIP was injected into the peptide’s flask using a 
gas-tight Hamilton glass syringe with a Teflon plunger, at a peptide’s 
concentration of 1 mM.  
 
Table 4. General Specifications of Amyloid Beta Peptides Used in this Study 
Characteristic Aß1-40 (Amyloid Beta 1-40) 
Aß1-42 
(Amyloid Beta 1-42) 
 
Sequence 
 
Asp-Ala-Glu-Phe-Arg-
His-Asp-Ser-Gly-Tyr-
Glu-Val-His-His-Gln-
Lys-Leu-Val-Phe-Phe-
Alabh-Glu-Asp-Val-Gly-
Ser-Asn-Lys-Gly-Ala-Ile-
Ile-Gly-Leu-Met-Val-Gly-
Gly-Val-Val 
 
Asp-Ala-Glu-Phe-Arg-
His-Asp-Ser-Gly-Tyr-Glu-
Val-His-His-Gln-Lys-Leu-
Val-Phe-Phe-Ala-Glu-
Asp-Val-Gly-Ser-Asn-
Lys-Gly-Ala-Ile-Ile-Gly-
Leu-Met-Val-Gly-Gly-Val-
Val-Ile-Ala 
 
MW (a.m.u.) 
 
4,329.9 
 
4,514.1 
 
Formula 
 
C194H295N53O58S1 
 
C199H307N53O59S1 
 
Purity (HPLC Analysis) 
 
97.2% 
 
87.2% 
 
Solubility 
 
1mg/ml in water 
 
1 mg/ml in 0.05M Tris 
buffer 
 
Counter ion 
 
Trifluoroacetate 
 
Trifluoroacetate 
 
American Peptide Cat. No. 
 
62-0-78 
 
62-0-80 
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The peptide immediately dissolves because of the high polarity of the 
HFIP, that helps to break down the peptide’s pre-existing tertiary structures [37]. 
After 10 minutes in HFIP at 25°C, the peptide was aliquoted in sterile 
microcentrifuge tubes and left overnight in a laminar-flow cabinet (Class 100) 
allowing the HFIP to evaporate.  This protocol created a clear peptide film in the 
bottom of each vial.  Each film was also exposed to 30 in Hg of vacuum for 8 
hours to eliminate traces of HFIP and humidity.  Each vial was closed with 
nitrogen (gas), and sealed with Parafilm-M.  Finally, all the vials were stored at -
20°C in a jar containing molecular sieves and closed with nitrogen to maintain a 
low humidity environment. 
 
4.1.2. Aß Monomers under Different Media Conditions 
Figure 19 illustrates the protocol followed to understand and identify the 
initial molecular conformation and morphology of Aß peptides under media 
conditions that at different incubation times promote defined monomers, 
oligomers, and fibrils. Aß1-40, Aß1-42, and Aß40/42 peptides were exposed to the 
conditions explained below and monitored until stability was reached.  That is, 
the peptides were monitored 30 minutes at conditions (a)-(c); and for 1 hour at 
conditions (d) and (e). 
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Figure 19 explains the details of this study as follows: 
Figure 19(a): each peptide was dissolved in HFIP at 1mM concentration, 
as described in the pre-treatment step (section 4.1.1), and allowed to equilibrate 
for 30 minutes in a gas tight ATR flow cell. Continuous spectra were collected 
during this period.   
 Figure 19(b): Once the HFIP evaporates a film is formed, it was 
determined if monomeric species were maintained. Thus, in a second experiment 
each peptide dissolved in HFIP as described in Figure 19 (a) was deposited on 
an open ATR trough plate. Then, the HFIP was removed by evaporation assisted 
by a dry nitrogen (gas) stream.  Continuous spectra were collected for each 
peptide film during 30 minutes. In addition, a 5 #l drop of this solution was 
deposited on freshly cleaved mica and the film was later imaged with atomic 
force microscopy (AFM) to relate peptide’s structure to its morphology. 
 Figure 19(c): When oligomers or fibrils are prepared, the peptide’s film is 
always re-dissolved in DMSO to 5 mM concentration.  
 Figure 19(d): The above solution (c) is taken to 100 #M (0.1 mM) using 20 
mM Tris buffer solution (2.42g Tris Base pH 7.4 w/HCl, prepared in 1L of 
solution) to prepared oligomers.  
 Figure 19(e): To prepare fibrils, solution (c) is diluted to 100 #M with 0.01 
M phosphate-buffered saline solution. 
AFM was used to analyze the morphology of Aß1-40, Aß1-42, and Aß40/42,as 
prepared in Figures 19(d) and 19(e). 
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Figure 19. Systematic Study of Aß Monomers under Different Media Conditions. 
(a) Aß peptide is dissolved in HFIP and monitored with ATR-FTIR spectroscopy; 
(b) the HFIP is evaporated from the peptides’ solution leaving a film; (c) the 
peptide’s film is redissolved with DMSO; (d) The peptide dissolved in DMSO is 
diluted to 100#M with TRIS solution to obtain stable oligomers; (e) The peptide 
dissolved in DMSO is diluted to 100#M with 0.01M PBS solution to obtain fibrils 
 
4.1.3. Oligomers Stability and their Characteristic Secondary Structure 
The morphology and secondary structure dynamics of the oligomeric 
intermediate species of the Aß peptides was characterized. The oligomers were 
prepared following a method established in a preliminary study [81].  Briefly, the 
peptide film was dissolved in DMSO  (5 mM) and diluted to 100 #M (0.1 mM) with 
a 20 mM Tris buffer solution (2.42 g/L Tris Base at pH 7.4 adjusted with HCl).  
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The solution prepared to form oligomers was split in two portions, one 
portion was injected in an ATR flow cell to follow in situ the evolution in 
secondary structures at 25°C; the second portion of the oligomeric solution was 
aliquoted and incubated at the same temperature (25°C); each aliquot was 
retrieved at different times during 48 hours for later AFM analysis. 
 
4.1.4. Aß Species and Kinetics of Fibril Formation 
The first step to promote fibril formation was to re-dissolve the peptide film 
with DMSO until it reached concentration of 5 mM, the dissolution process was 
assisted by 5 minutes of sonication. This was followed by the addition of PBS 
(0.01 M, pH 7.4), diluting the peptide solution to 100 #M.  After 1 minute of 
sonication the solution was split in two portions, the first one was injected in the 
ATR flow cell for spectroscopy analysis (incubated at 25°C) and the second 
portion was aliquoted for AFM analysis. Aliquots retrieved at different time points. 
 
4.1.5. Peptide Secondary Structure Study: Attenuated Total Reflection 
Fourier Transform Infrared (ATR-FTIR) Spectroscopy 
Once the accessory was assembled and prior to injecting the peptide 
solution, a portion of fresh peptide-free incubation media solution was flushed 
through the cell in each new experiment. Spectra and background of this media 
in contact with the crystal were obtained. The peptide-free solution background 
was used to eliminate the solvent contribution in the peptides solutions. The 
experiments were run for 30 minutes for monomer characterization, and for 48 
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hours for oligomeric and fibril formation. Oligomers and fibrils solutions were set 
up to collect a new spectrum every 10 minutes. 
 
4.2. Results, Analysis and Discussion 
 This section shows and discuses the particular characteristics of the Aß 
species, beginning with the monomeric species of the two isoforms Aß peptides 
(Aß1-40 and Aß1-42) and their equimolar mixture; moving on to the oligomers and 
fibrils characterization for each peptide.  
 
4.2.1. Species of Aß Peptides 
 During peptide aggregation different species can be found and defined. 
However, referred here as monomer, oligomers, and fibrils as species of the Aß 
peptide.  
 
4.2.1.1. Aß Peptide Monomers  
This first study was designed to determine the characteristic content of 
secondary structure present in the monomeric specie of Aß peptides.   
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Figure 20.  Amide I and II Regions of Aß1-40 Monomers in HFIP. The spectra 
displayed here were collected for Aß1-40 during 30 minutes of incubation in HFIP 
at 1mM. The amide I region shows that the antiparallel ß-sheet are the dominant 
structures within the monomeric species. The lack of absorbance in the amide II 
region is evidence of the absence of protein adsorption, hence all the monomeric 
species are in solution 
 
Aß1-40 peptide dissolved in HFIP was injected in a hermetic ATR flow cell 
accessory and monitor over 30 minutes with ATR-FTIR spectrometry. Figure 21 
shows that monomers are unequivocally detected in HFIP, confirmed by the lack 
of protein adsorption revealed by the amide II region. 
After deconvolution of the amide I region for each time shown in Figure 20 
with clear center in the antiparallel ß-sheet band (1624 cm-1), it is possible to 
obtain the information plotted in Figures 21(a) and 21(b), showing the evolution 
of secondary structures during 30 minutes of incubation. 
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Figure 21. Secondary Structures of Aß1-40 Monomers in HFIP. (a) Secondary 
structures evolution of the monomers in solution. (b) Secondary structure content 
change for the monomeric species. Each point in this plot was calculated by 
integrating the area under the curve corresponding to the different specific IR 
bands defining each secondary structure (Shown in Table 1) at the times shown 
in (a). Observe in that after 10 minutes the structures start reaching equilibrium 
and between 27 and 30 minutes stabilize 
 
Figure 21(a) shows the increase of antiparallel and parallel ß-sheets 
secondary structures during 30 minutes of incubation in HFIP, this figure 
suggests that the monomers are constantly evolving but they do not aggregate. 
However the dominant configuration of the monomeric species is the antiparallel 
ß-sheet type, Figure 21(b). 
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Figure 22. Secondary Structure Content of Aß1-40 Peptide Monomeric Film. (a) 
The shift of amide I and the appearance of amide II show a significant difference 
when protein adsorption occurs.  (b) Comparison of secondary structure content 
change before (light color bars) and after (solid bars) HFIP has evaporated. Main 
differences are observed, as the switch from antiparallel ß-sheet structures to 
parallel ß-sheets with a larger influence of "-helix structures 
 
Continuing with the study of Aß1-40 peptide, once the HFIP solvent 
evaporates, it leaves a film with characteristic secondary structures, shown in 
Figure 22. The shift of the amide I region in this figure confirms that when the 
peptides absorb to the crystal, parallel ß-sheet structures are highly involved in 
this process.  Protein adsorption (film formation) is verified by analyzing the 
amide II region (Figure 22(a)).  
Figure 22(b) compares the content of secondary structures of the peptide 
before and after the HFIP is evaporated (film formation). The monomeric film is 
characterized by the dominant content of parallel ß-sheets and "-helix structures, 
with decrease of antiparallel ß-sheet structures, this confirms that the peptide is 
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not in solution anymore. It is important to note that the antiparallel ß-sheet 
structure was significantly reduced as the film was formed. 
The results for Aß1-40 shows that 30 minutes (Figure 21(b)) is a reasonable 
incubation time in HFIP for the peptide (also found for the cases of Aß1-42 and 
Aß40/42) to have its secondary structure in equilibrium. The two peptides and their 
1:1 combination under study (Aß1-40, Aß1-42 and Aß40/42) were incubated for        
30 minutes in HFIP as an initial practice for all experiments involving these 
peptides.  Comparison of the monomeric species in HFIP for Aß1-40, Aß1-42 and 
their equimolar combination is shown in Figure 23. 
It is important to note that Aß1-42 peptide shows an antiparallel ß-sheet to 
"-helix ratio close to 1 (0.85) in its monomeric state. In previous work (Jimenez, 
2005 [72]) "-helix structures were found to play an important role during fibril 
formation of Aß1-42 peptide. Hence, it is not surprising to find antiparallel ß-sheet 
structures competing with "-helix structures in its monomeric state.  
Prion proteins capable of amyloid formation exhibit similar characteristics 
when forming fibrils; with similar roles played by antiparallel and "-helix 
structures.  This is evidenced in a NMR study performed to the prion protein 
domain PrP(121-231).  This domain contains most of the point-mutation sites 
known to infectious prion proteins that form two-stranded antiparallel ß-sheet and 
three "-helices [82].  
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Figure 23. Secondary Structure of Amyloid Peptides Monomers in HFIP. (a) 
Amide I region, spectra corresponding to 30 minutes of incubation in HFIP for 
Aß1-40, Aß1-42, and Aß40/42. (b) Secondary structure content corresponding to the 
monomers of Aß1-40, Aß1-42, and Aß40/42 in HFIP. The values shown in this plot 
were obtained by averaging the spectra shown in (a) and the error bars are the 
standard deviations. Notice that, antiparallel ß-sheet (blue) is the dominant 
structure in Aß1-40 and Aß40/42 monomeric species.  When in the case of Aß1-42 
both antiparallel and "-helix (green) structures dominate the monomeric species 
(c) Schematic approximation of two Aß monomers mainly showing antiparallel ß-
sheet and small regions of "-helix structures (image representing the dimer of 
transthyretin, shown with permission of Landry, 1996) 
 
The results found in this study, revealed the importance of antiparallel 
structures to stabilize folded monomers in solution. Note that one would find 
parallel ß-sheet structures as well as part of the overall structure. However, the 
dominant secondary structure in all 3 cases is the antiparallel ß-sheet.  This 
observation, is in agreement with the name given to the Alzheimer’s disease 
amyloid peptide, that is amyloid “Beta” peptide, due to the high content in ß-sheet 
structures in its monomeric folded state [83, 84].  Figure 23(c) is an schematic 
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approximation of two amyloid forming monomers, with permission of Landry, 
1996, this picture represents the antiparallel beta sheet in equilibrium with small 
domain of "-helix structures. This model is in agreement with our results. 
The study performed to Aß1-40 of HFIP evaporation (Figure 22) and film 
formation, was repeated for Aß1-42 and the peptide equimolar mixture Aß40/42, the 
results comparing the secondary structure content for each case are shown in 
Figure 24.   
 
  
Figure 24. Change in Content of Secondary Structure for Amyloid Peptides 
during Monomeric Film Formation. (a) Amide I and II regions for Aß1-40, Aß1-42, 
and Aß40/42. (b) Comparison of secondary structure content before and after the 
HFIP evaporates, Aß peptides dissolved in HFIP (light color bars) versus their 
films (solid bars) 
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In general, Figure 24(a) shows that when a film is formed, there is a 
significant shift in the secondary structures (amide I), and a prominent absorption 
in the amide II region. Figure 24(b) shows that the deposition is mainly 
dominated by parallel ß-sheet structures, while the monomeric state in solution is 
dominated by antiparallel ß-sheet structures.  
Figure 25(a) shows the characteristic morphology of Aß1-40 and Aß1-42 
monomeric films; which were obtained by depositing the peptide dissolved in 
HFIP on freshly cleaved mica as explained in 3.1.2.1. Figure 25(b) shows the 
height distribution analysis for the films from Figure 25(a) corresponding to Aß1-40 
and Aß1-42 peptides. Aß1-42 peptide formed more dense films than Aß1-40, this can 
be explained by the hydrophobic nature of Aß1-42 peptide, which reduces steric 
interaction promoting a denser film.  Two other studies (Harper in 1997, and 
Shao in 1999) are in agreement with the hydrophobic nature and ability to pack 
conferred to Aß1-42 peptide [85, 86].  
 In addition to these studies with HFIP, Figure 26 shows the results after 
the peptide films are redissolved with DMSO, since this is the protocol followed 
prior to oligomeric or fibrillar preparations.  
As Figure 26 shows the action of DMSO is to redissolve the peptide and 
stabilize the secondary structure content. However, when oligomeric and fibrillar 
solutions are prepared, sonication is an important step to ensure the 
redissolution of the film.  Notice that the film after DMSO addition shown in 
Figure 26 was not sonicated.  
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Figure 25. Morphology of Monomeric Peptides Film. (a) AFM image of Aß1-40 
(top) and Aß1-42 (bottom) peptide monomers on mica (scan size: 0.5x0.5-#m x-y); 
(b) Gaussian distribution of the heights found in each case (topography), please 
observe that the Aß1-42 film has a less dispersed distribution (red line, centered at 
1nm) 
 
In general, this study has proven that when peptides are pre-treated with 
HFIP, their conformations in solution are reduced to their monomeric form.  This 
results in a homogeneous (monomeric) film when the HFIP is allowed to 
evaporate.  This is the rationale for pre-treating the peptides with HFIP as a 
homogenizing point prior to prepare any peptide solution. 
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Figure 26. Spectroscopy Analysis for Aß Peptide Monomers in DMSO. (a) Amide 
I and II regions for Aß1-40, Aß1-42, and Aß40/42, the amide I region shows that the 
peptides dissolved in DMSO are structurally stable (no shift), the absorption 
observed in the amide II region shows that there is peptide remaining as a film. 
(b) Secondary structure content by peptides, comparison between the dry 
peptide film (light color bars) and the peptide redissolved in DMSO solid bars). 
Note that in all three cases antiparallel ß-sheet structures increased in DMSO 
 
4.2.1.2.  Oligomeric Species of the Aß Peptides  
Oligomers are the intermediate species in the formation of fibrils [87]. 
Understanding the stability and secondary structure characteristics of these 
species is key to explain fibril formation and disruption (which will be discussed in 
chapters 5 and 6 in detail). This study also characterized the kinetics of 
secondary structures responsible for the formation and stability of oligomeric 
species of Aß peptides. The study is presented by peptide type. 
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4.2.1.2.1. Oligomers of Aß1-40 Peptide 
 Two stages of the oligomerization process were monitored in this study.  
First, the peptide dissolution and hydration taking place in the initial 60 minutes of 
incubation (Figure 27); and second, the formation and stabilization of the 
oligomeric species during 48 hour of incubation (Figure 28). 
Molecular rearrangement is observed in the first 60 minutes of incubation 
(Figure 27).  During the first 10 minutes antiparallel ß-sheets and "-helix are the 
dominant structures; at this point monomers are mainly in solution. After 10 
minutes of incubation, the structures shift with increase in parallel ß-sheets 
structures, this is the moment that marks the beginning of the oligomerization 
process (Figure 27(c)).  
Figure 28 (a) shows the spectra corresponding to 48 hour of total 
incubation, represented by the multicolored lines.  Figure 28(b) shows the same 
48 hour of total incubation in grey but representing time ranges of 4 hours in red.  
This visualization technique provides a quick way to observe progressive spectral 
changes, and assess variance visually; for the whole amide spectra, or for the 
amides I and II independently. 
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Figure 27. Spectroscopy Study of Aß1-40 Peptide during the First 60 Minutes of 
Incubation in DMSO+TRIS Solution at 25°C. (a) Amide I and II regions, spectra 
from 0 to 60 minutes, amide II shows protein adsorption, on amide I region 
shifting can be observed showing secondary structure instability. (b) Comparison 
of the total integrated absorbance of amide I vs. amide II from 0 to 60 minutes. 
(c) Reorganization of the secondary structure that assists the process of 
aggregation into stable oligomers.  (d) Evolution of secondary structure content 
of Aß1-40 the first 60 minutes of incubation 
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Figure 28. Kinetics of Aß1-40 Oligomers in DMSO+TRIS Solution at 25°C. (a) 
Spectra of the Amide I and II regions for Aß1-40 peptide during 48 hours of 
incubation at 25°C. (b) Sets of spectra selected each 4 hours (red spectra), 
during 0 to 48 hour of incubation 
 
Figure 29(a) shows the average spectra calculated from the time frames 
shown in Figure 28(b). The average spectra were calculated using  (Eq.1) from 
Section 3.3.1.4.  Figure 29(b) shows the %Variance calculated with (Eq.3) also 
from Section 3.3.1.4.  
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Figure 29. Aß1-40 Average Spectra and Variance Percentage. (a) Spectra 
obtained from averaging the 4 hours range as shown in (Eq.1); (b) %Variance for 
each time point corresponding to Amide I and II separately and individually, 
observe that when values are under 30% of variance (Eq.3) the calculation is 
considered to be statistically acceptable, more variability than this values reflects 
instability of the sample in that range of time 
 
The analysis of the amide I and II regions for Aß1-40 peptide incubated in 
DMSO+TRIS solution is shown in Figure 30(a), it represents the behavior of   
Aß1-40 during the formation of stable oligomeric species during 48 hours. (b) 
Shows the changes exhibited by the amide I and II regions each 4 hour time 
frame (averaged spectra) with overall activity in secondary structure (amide I) 
and adsorption (amide II).  As the deconvolution of amide I spectra reveals in (c), 
all secondary structures increase for every structure in absolute absorbance 
values. However, when these values are normalized Figure 30(d) reveals that the 
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overall content of parallel structures increases while antiparallel structures 
decrease during the formation and stabilization of Aß1-40 oligomers. 
  
  
Figure 30. Analysis of the Amide I and II for Aß1-40 Oligomers in DMSO+TRIS 
Solution. (a) Averaged spectra using (Eq.1) from Section 3.3.1.4. (b) Change of 
integrated absorbance under the amide I and II during the incubation period. (c) 
Secondary structure kinetics of Aß1-40 in DMSO+TRIS during 48 hour of 
incubation. (d) Change in secondary structure content for Aß1-40 in DMSO+TRIS 
during 48 hour of incubation 
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Figure 31. Morphology of Aß1-40 Oligomers over 48 Hours of Incubation. (a) 1x1-
#m x-y scans of Aß1-40 from 0.5h to 48h of incubation.  (b) Average diameter of 
the oligomers encountered in solution at different incubation times 
 
Figure 31(a) shows the morphology of Aß1-40 oligomers through time, 
these images have a scan size of 1x1-!m x-y.  Results in Figure 31(b) show the 
average diameter of the oligomeric species shown in Figure 31(a), and it can be 
observed that these species maintained their structure and shape over 48 hours 
incubation in DMSO+Tris (2:98 volume to volume) at 25°C.  
 
4.2.1.2.2. Oligomers of Aß1-42 Peptide 
 
As in the previous study (4.2.1.2.1), this section investigates the stability of 
Aß1-42 oligomeric species using two timeframes: during the first hour (Figure 26) 
of incubation (in DMSO and TRIS solution at 25°C, Figure 32) and during 48 hour 
to monitor stability. 
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Figure 32. Change of Secondary Structures of Aß1-42 Dissolved in DMSO after 
Diluting with TRIS Buffer Solution to 100 #M. (a) Spectra of the Amide I and II 
regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I 
region shifting can be observed showing instabilities; (b) Comparison between 
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c) 
Reorganization of the secondary structure that trigger a process of aggregation 
into oligomers is shown;  (d) Change of secondary structure content of Aß1-42 in 
the first 60 minutes of incubation 
 
Figure 32 shows progression of spectra collected during the first hour of 
Aß1-42 oligomeric species production in DMSO+TRIS buffer at 25°C.  It is 
important to indicate that the predominant species are antiparallel !-sheet and "-
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helix as it can be seen in 32(d); this behavior was also observed in the case 
studied in section 4.2.1.1 for Aß1-42 monomers in HFIP (Figure 23(b)). 
For the case of 48 hours study, the spectra of the Aß1-42 oligomers (Figure 
33(a)) showed some instability as evidenced by the Figure 33(b) and Figure 
34(b), not reaching and stable spectra trajectory and reflected on the variability 
from time to time. However, this was not an impediment for the oligomeric 
structure to form and be stable (Figure 35). The explanation for this movement 
among the spectra might be due to the fact that these oligomers are in a reactive 
state, therefore the structures and even the adsorption varied from spectrum to 
spectrum.  
Even as the stability of Aß1-42 oligomers lags behind that of Aß1-40, it is 
evident that at all times "-helix and antiparallel ! sheet are the dominant 
structures contained and stabilizing the oligomeric species (Figures 34(c) and 
(d)) of Aß1-42 peptide. Figures 34(c) and (d) are the result of deconvoluting the 
average spectra shown in Figure 34(a).  
 
  
Figure 33. Amide I and II of Aß1-42 Oligomers during Oligomerization. (a) Spectra 
of the amide I and II regions for Aß1-42 in DMSO+PBS during 48 hours of 
incubation at 25°C. (b) Spectra selected in  4 hours ranges (red spectra) 
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Figure 34. Kinetics of Aß1-42 Oligomers in DMSO+TRIS Solution. (a) Average 
spectra obtained from the 4 hours range shown in Figure 33(b).  (d) Variances 
calculated from 33(b) for the average spectra. (c) Secondary evolution of Aß1-42 
in DMSO+TRIS during 48 hour of incubation.  (d) Change of secondary structure 
content for Aß1-42 in DMSO+TRIS during 48 hour of incubation 
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Figure 35. Morphology of Aß1-42 Oligomers. (a) 1x1-#m x-y scans of Aß1-42 from 
0.5h- 48h of incubation.  (b) Average diameter of the oligomers encountered in 
solution at different incubation times, even when at 12 hour and 24 fibrils are 
shown, they are rarely found, this fibrils have diameters in the range of the 
oligomeric species (35±10nm) 
 
 The progression of AFM scans of Aß1-42 oligomeric species in Figure 35 
(a), and the analysis of particle sizes in (b) show changes in size of oligomers 
that stabilizes after 24 hours.  Even though fibrils were observed in AFM 
experiments, these were scarce and did not play an important role in the 
morphology of aggregates, which were dominated by Aß1-42 oligomeric species. 
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4.2.1.2.3. Oligomers of Aß40/42 Peptide 
  
 The study in this section mirrors the two preceding studies but tests a 
combination of both peptide Aß1-40 and Aß1-42 at a molar ratio of 1:1. Similarly to 
Aß1-40 and Aß1-42 oligomeric study, ATR-FTIR spectroscopy and AFM analysis 
were performed for 1 hour and 48 hour time scopes. 
 
    
 
 
 
 
  
  
Figure 36. Change of Secondary Structures of Aß40/42 Incubated in DMSO and 
TRIS at 25°C. (a) Spectra of the Amide I and II regions from 0 to 60 minutes, 
Amide II shows protein adsorption, on Amide I region shifting can be observed 
noting instabilities; (b) Reorganization of the secondary structure that trigger the 
process of oligomers formation;  (c) Change in secondary structure present in the  
Aß40/42 peptides during the first 60 minutes of incubation in DMSO+TRIS solution 
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 Figure 36(a) shows the spectra (amide I and II regions) corresponding to 
the initial 60 minutes of incubation,  (b) shows the decreased and stabilization of 
the evolution for antiparallel structures and the rest, respectively. Figure 36(c) 
shows that antiparallel ß-sheet structures are dominant in this first hour of 
incubation. 
 
  
Figure 37. Kinetics of Aß40/42 Oligomers in DMSO+TRIS Solution. (a) Spectra of 
the Amide I and II regions for Aß40/42 peptide spectra during 48 hours of 
incubation at 25°C; (b) Sets of spectra selected each 4 hours (red spectra), 
during 0 to 48 hour of incubation 
 
 Figure 37(a) shows the spectra collected from 0 to 48 hours of incubation, 
representing only the amide I and II regions of the spectrum, (b) explains 
schematically the process of time sets selection. The stability spectral analysis 
for Aß40/42 oligomers shown in Figure 38 (b) and corresponding to the average 
spectra in (a), shows that after 12 hours of incubation the oligomers reach 
stability.  This can also be visually observed in figure 37(b). 
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Figure 38. Kinetics and Change of Secondary Structure Content of Aß40./42 
Oligomers Prepared in DMSO+TRIS Solution. (a) Spectra obtained from 
averaging the 4 hours range as shown in Figure 37(b); (b) Percentage of 
variance calculated for each average spectra in (a) from the data shown in Figure 
37(b). (c) Secondary structure evolution of Aß40/42 in DMSO+TRIS during 48 hour 
of incubation;  (d) Change in secondary structure content for Aß40/42 in 
DMSO+TRIS during 48 hour of incubation 
 
 During the first 60 minutes of the stability study, the oligomeric equimolar 
mixture of Aß40./42 seems to reach relative stable conformations (Figure 36(c)), 
after this short initial time, the peptide mixture shows and increase in antiparallel 
ß-sheet dominating over the second structure increasing, the parallel ß-sheets.  
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 AFM analysis was performed to this peptide combination, finding no 
evidence of adsorption to the mica at any time, suggesting that the oligomers in 
the ATR crystal are in a dynamic equilibrium of adsorption and desorption, 
explaining the adsorption shown in Figure 39, and at the same time the absence 
in the mica surface (not shown). 
 
 
Figure 39. Kinetics of Aß Oligomeric Species Adsorption. The values shown in 
this plot are the integrated areas under each amide II region corresponding to 
each different time, and as explained in section  3.3.1.2 it corresponds to the 
peptide adsorption on the ATR crystal 
 
 A comparison of the first 48 hours of oligomeric adsorption values from the 
Amide II region in Figure 39 reveals that Aß1-40 has the most adsorption tendency 
to the FTIR crystal while Aß1-42 has a comparable adsorption to the peptides 
mixture; still Aß40./42 has a value in between the individual peptides.   
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4.2.1.3. Fibrillization of Aß Peptides at 25°C 
The main focus of this work is to understand and obtain the necessary 
knowledge to interpret the mechanisms of peptide fibrillization, to then be able to 
target a dissolution process (this will be discuss in Chapters 5 and 6). In the 
amyloid hypothesis, it is stated that when an imbalance in the amyloid peptide 
production and clearance equilibrium is altered, this drives to Aß plaque 
formation [88, 89], initiating a cascade of effects that ultimately lead to neuronal 
death, hence understanding the process of peptide aggregation at the molecular 
lever is important to treat the disease.   
This study parallels the previous sections for monomers and oligomers of 
Aß40., Aß42 and the equimolar mixture of Aß40./42.  In this set of experiments, the 
peptide film dissolved in DMSO was diluted to 100#M with PBS and incubated at 
25°C, protocol that yields to fibril formation [72].  
4.2.1.3.1 Aß1-40 Fibrils 
 Aß1-40 fibrils were studied for both time scopes of 60 minutes and up to 96 
hours, the samples were analyzed with ATR-FTIR spectroscopy and AFM. 
The first 60 minutes of Aß1-40  fibril formation of process have very little 
stability as it is evidenced by the changes in spectra shown in Figure 40(a), the 
integrated absorbance of the Amide I and Amide II in (b), and absolute and 
relative structure content values from (c), and (d). 
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Figure 40. Change of Secondary Structures of Aß1-40 Prepared in DMSO+PBS 
Solution and Incubated at 25°C. (a) Spectra of the Amide I and II regions from 0 
to 60 minutes, Amide II shows protein adsorption, on Amide I region shifting can 
be observed showing the molecular rearranging of the molecules; (b) 
Comparison between Amide I and Amide II integrated absorbance from 0 to 60 
minutes; (c) Reorganization of the secondary structure that trigger the process of 
peptide aggregation;  (d) Change of secondary structure content of Aß1-40 in the 
first 60 minutes of incubation 
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Figure 41. Fibrillization of Aß1-40 in DMSO+PBS. The fibril are formed at 25°C 
and monitored during 96 hours. (a) Amide I (1700-1600 cm-1) and amide II (1600-
1500 cm-1) spectra.  (b) Amide I region, spectra selection shown up to 48 hours; 
this study is performed to evaluate the stability and structural change of the 
peptides.  (c) Average spectra calculated from the selected times in (b) 
  
The stability analysis presented in Figure 41 allows observing the limited 
stability of the fibrils formed by Aß1-40 in PBS until more than 80 hours as average 
spectra show in (c); time frame not shown in (b). 
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Figure 42. Fibrillization of Aß1-40 and Secondary Structures Change. (a) 
Morphological change monitored with AFM. (b) Most relevant secondary 
structures kinetics. (c) Most relevant secondary structure content 
 
Figure 42(a) shows the progression of fibril formation for up to 240 hours 
for the AFM scans, and 96 hours for FTIR amide I secondary structure content.  
The analysis shows that fibrils are stable at more than 80 hours and the 
predominant structures are antiparallel !-sheet and "-helix for formed fibrils. 
 
4.2.1.3.2. Aß1-42 Fibrils 
Aß42 fibrils were studied under FTIR-ATR and AFM analysis for both time 
scopes of 60 minutes and 240 hours, the analyzed data is presented in this 
section. 
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Figure 43. Change of Secondary Structures of Aß1-42 Prepared in DMSO+PBS 
Buffer Solution to 100 #M and Incubated at 25°C. (a) Spectra of the Amide I and 
II regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I 
region shifting can be observed showing instabilities; (b) Comparison between 
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c) 
Reorganization of the secondary structure that trigger a process of aggregation 
into oligomers is shown;  (d) Change of secondary structure content of Aß1-42 in 
the first 60 minutes of incubation 
 
 Aß1-42 process of fibril formation reaches relative stability at 30 minutes as 
it is evidenced by the changes in spectra in Figure 43(a), this is further confirmed 
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by the changes in absorbance of the Amide I and Amide II in (b), and absolute 
and relative structure content values from (c), and (d). 
 
 
 
 
Figure 44. Fibrillization of Aß1-42 at 25°C. (a) 0 to 72 hours spectra during the 
Aß1-42 peptide aggregation. (b) Aggregation evolution by time ranges. (c) 
Averages spectra calculated from (b) 
 
 The stability analysis presented in Figure 44 shows the relatively high 
stability of the fibrils formed by Aß1-42 in PBS which increases in the 72 hours of 
the study, as stability visualization in (b), and as average spectra show in (c). 
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Figure 45. Secondary Structure Change during Fibrillization of Aß1-42 at 25°C. (a) 
Rate of aggregation per structure. (b) Percentage change of secondary structure 
content. (c) AFM morphological characterization of the Aß1-42 fibril formation 
 
 
 Figure 45 shows secondary structure analysis of FTIR-ATR data for up to 
96 hours shows that the remaining dominant secondary structure over the long 
term evolution of fibrils is parallel !-sheets structure. 
 The AFM scans on Figure 45(c) show that the morphology of the fibrils 
change over the 240h scan which is in agreement with the secondary structure 
analysis in Figure 45(b) in which only parallel ß-sheet structure remains dominant 
among other secondary structures. 
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4.2.1.3.3. Aß40/42 Fibrils 
 The fibrillation process of Aß1-40 and Aß1-42 at a ratio of 1:1 and at 25°C 
was investigated in this section.  As for the previous cases, the study was done 
for the first hour and then for up to 96 hours. 
 
  
 
 
 
 
 
 
Figure 46. Change of Secondary Structures of Aß40/42 Dissolved in DMSO after 
Diluting with PBS Buffer Solution to 100 #M. (a) Spectra of the Amide I and II 
regions from 0 to 60 minutes, Amide II shows protein adsorption, on Amide I 
region shifting can be observed showing instabilities; (b) Comparison between 
Amide I and Amide II integrated absorbance from 0 to 60 minutes; (c) 
Reorganization of the secondary structure that trigger a process of aggregation 
into oligomers is shown;  (d) Change of secondary structure content of Aß40/42 in 
the first 60 minutes of incubation 
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 Figure 46 shows the first hour evolution of the fibrillization process the 
Aß40/42 equimolar mixture, which initially has as dominant secondary structure, 
antiparallel !-sheets. 
 
  
Figure 47. Fibrillization of Aß40/42 at 25°C. (a) 0 to 72 hours spectra during the 
Aß1-42 peptide aggregation. (b) Aggregation evolution by time ranges 
 
 The stability analysis of the Aß40/42 depicted in Figure 47, shows little 
stability of the fibrils during the 72 hour timeframe. 
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Figure 48. Fibrillization of Aß40/42 at 25°C. (a) Spectra average by time range, (b) 
AFM morphological characterization of the Aß40/42 fibril formation (c) Most 
relevant structures changing during fibrillization, (b) Percentage change of most 
relevant secondary structures 
 
 The morphology of the Aß40/42 fibrils depicted in Figure 48, shows parallel 
!-sheets as the dominant structure for most of the process on the long term 
analysis. 
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Figure 49. Comparing the Morphological Evolution of Aß Peptides during Fibril 
Formation at 25°C. (a) AFM morphology characterization. (b) TEM images of Aß 
peptides at 10 days of incubation 
 
 The AFM scans and TEM images in Figure 49 provide an opportunity to 
compare the morphology of fiber formed by either Aß1-40 and Aß1-42 peptide, as 
well as their 1:1 combination.  AFM scans at 1x1!m reveal that fibrils formed by 
the mix of peptides Aß40/42 are generally thicker and formed of globular 
aggregates; this is the case for initial fibril structures formed in Aß1-40. 
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Figure 50. Morphology of Aß Peptides Films Prepared in DMSO + TRIS and 
DMSO + PBS Solution. The Films shown in (a) where obtained 30 minutes after 
the samples were prepared. (b) Topographical analysis of oligomers in       
DMSO + TRIS solution; (c) Topographical analysis of oligomers in DMSO + PBS 
solution 
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The observations of morphology about fibrils formed from the peptide 
equimolar mixture of Aß40/42 is mirrored by the morphology of oligomeric 
aggregates shown in Figure 50(a).  Quantification of such aggregates from AFM 
scans show that in the case of the TRIS solution, the size of oligomeric 
aggregates from Aß1-40 are smaller with smaller average height, Aß1-42 are larger 
in size, and the size of oligomers from the mix Aß40/42 appear in between those of 
the peptides.  This is not the case for oligomeric aggregates in PBS solution 
shown in 50(b); which are considerably larger for the mix Aß40/42 than those for 
each peptide on their own.  This morphological behavior is similar to that shown 
for fibrils in Figure 49. 
4.2.1.4. Effects of Temperature during the Fibrillization of Aß Peptides  
This section introduces two new studies complementary to the Aß 
peptides fibrillization assessment. Now, varying the incubation temperature to 
37°C. these studies are only performed for Aß1-42 and Aß40/42 peptides. 
4.2.1.4.1. Aß1-42 Fibrils 
Figure 51 shows the evolution of both amides (I and II) during the process 
of fibril formation at 37C. Amide II shows adsorption of protein. Amide I region 
shows molecular rearrangement better appreciate it in Figure 51(b).  As 
previously explained, Figure 51(c) represents the average spectra for the 4 hours 
ranges selected from Figure 51(b), and the analysis of secondary structure is 
(performed to the amide I region) is shown in Figure 52(a) and (b). 
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Figure 51.  Aß1-42 Peptide Fibrillization at 37°C. (a) Spectra from 0 to 96 hours of 
incubation.  (b) Time selection by ranges.  (c) Average spectra calculated per 
time range selected in (b) 
 
 Figure 52(b) shows the parallel structures as the dominant conformation 
along with the unordered structures. To assess the effect of temperature on the 
evolution of parallel and antiparallel structures, these structures are compared in 
Figures 52(c) and (d); it can be observed in these two figures that at 25°C the 
fibrillization process is more stable than at 37°C, however they both follow same 
path of aggregation. In addition the fibrils encountered at 48 hours of incubation 
have similar morphology in both cases (Figure 52(e).) 
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Figure 52. Aß1-42 Secondary Structure Change Effects of Temperature during 
Fibrillization.  (a) Kinetics of the secondary structures at 37C. (b) Content of the 
secondary structures change. (c) Temperature effect on the change of parallel ß-
sheet structures. (d) Temperature effect on the change of antiparallel ß-sheet 
structures. (e) Morphology of the Aß40/42 fibrils at 48 hours of incubation 
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4.2.4.1.2. Aß40/42 Fibrils 
Figure 53(a) shows the evolution of amide I and II for Aß40/42 when the 
incubation temperature is 37°C.  In Figure 53(b) the changes per 4 hour ranges 
of the two amides can be explored, and the averages of the time ranges are 
shown in Figure 53(c), the changes in morphology during the aggregation 
process is shown in Figure 53(d). 
 
 
 
 
Figure 53. Fibrillization of Aß40/42 at 37°C. (a) AFM morphological 
characterization of the Aß40/42 fibril formation. (b) Secondary structure as function 
of preferable energetic state during aggregation 
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Figure 54. Temperature Effect during the Fibrillization Process of Aß40/42. (a) 
Rate of aggregation per structure AFM morphological characterization of the 
Aß40/42 fibril formation. (b) Percentage change of secondary structure content.  (c) 
Temperature effect on the change of parallel ß-sheet structures. (d) Temperature 
effect on the change of antiparallel ß-sheet structures 
 
From Figure 53(c), the evolution of secondary structures in the amide I 
region was calculated and represented in Figures 54(a) and (b). These graphs 
correspond to the change in integrated absorbance and its normalized values 
respectively.  
 Figures 54 (c) and (d) compares the evolution of parallel and antiparallel   
ß-sheet structures at 25°C and 37°C; showing that at 37°C the fibrillization takes 
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place rapidly (first 12 hours of incubation) when it reaches equilibrium.  In 
comparison, the fibrillization process at 25°C, the stability of this process is 
reached at 40 hours of incubation.  In addition Figure 55 shows the morphology 
of fibrils, which have similar appearance at 48 hours of incubation.  
 
Figure 55. Comparison between Aß40/42 Fibrils Prepared at 25°C and 37°C. 
Images taken at 48hours of incubation with AFM at a scan size of 10x10#m x-y 
 
4.3. Chapter Remarks 
One important finding of this study is that preferentially, fibril formation is 
characterized by the increase of parallel ß-sheet structures, while if peptide 
species are in solution the preferential secondary structure is antiparallel ß-sheet 
configuration.    
The experiments and analysis in this chapter allowed the combinatorial 
study of two different Aß peptides isoforms Aß1-40, Aß1-42, and their equimolar 
mixture, Aß40/42.  The peptides were studied under 5 different set of conditions 
designed to control in different ways the aggregation of amyloid proteins.  The 
conditions allowed for the formation of monomers in solution, monomers on a 
film, oligomers, fibrils formed at 25°C, and fibrils formed at 37°C.  The stability of 
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the aggregation process and the dominant secondary structures were assessed 
to provide key knowledge in the understanding of the effect of monoclonal 
antibodies (mAb) on Aß peptides and their aggregation in later chapters. 
 The results from this chapter have been summarized in a Table 4, which 
allows comparing the different cases from the entire study. 
 
Table 5. Dominant Structures and Stability Table 
 
 Aß1-40 Aß1-42 Aß40/42 
HFIP Dominant 
Structures: 
Antiparallel !-sheet 
 
(stable) 
HFIP Dominant 
Structures: 
Antiparallel !-sheet 
"-Helix 
(stable) 
HFIP Dominant 
Structures: 
Antiparallel !-sheet 
 
(stable) 
Film Dominant 
Structures: 
Parallel !-sheets 
"-Helix 
 
(stable) 
Film Dominant 
Structures: 
Parallel !-sheets 
Antiparallel !- sheet 
"-Helix 
(stable) 
Film Dominant 
Structures: 
Parallel !-sheets 
"-Helix  
 
(stable) 
Monomers 
25°C 
DMSO Dominant 
Structures:  
Antiparallel !-sheet 
(stable)  
DMSO Dominant 
Structures:  
Antiparallel !-sheet 
(stable) 
DMSO Dominant 
Structures:  
Antiparallel !-sheet 
(stable) 
Oligomers 
25°C 
Dominant at 60 min: 
Parallel !-sheets 
Antiparallel !-sheet 
 (little stability) 
Dominant at 60 min: 
"-Helix  
Antiparallel !-sheet 
 (little stability) 
Dominant at 60 min: 
Antiparallel !-sheet 
 
(unstable) 
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Table 5. (Continued) 
 
 Aß1-40 Aß1-42 Aß40/42 
Oligomers 
25°C 
Dominant during 48 
hours: 
Parallel !-sheets 
 
(stable) 
Dominant during 48 
hours: 
"-Helix  
Antiparallel !-sheet 
 (moderate stability) 
Dominant during 48 
hours: 
Antiparallel !-sheet 
 Parallel !-sheets 
(moderate stability) 
Dominant at 60 min: 
No perceived 
dominance 
 
(unstable) 
Dominant at 60 min: 
Parallel !-sheets 
Antiparallel !-sheet 
"-Helix 
(apparent stability) 
Dominant at 60 min: 
Antiparallel !-sheet 
 
 
(moderate stability) 
Fibrils 
25°C 
Dominant during 48 
hours: 
Antiparallel !-sheet 
"-Helix 
 (moderate stability) 
Reduced after 48 
hours: 
Parallel ß-Sheets .  
 
Dominant during 48 
hours: 
Parallel !-sheets 
 
(stable) 
Dominant during 48 
hours: 
Parallel !-sheets 
 
 (moderate stability) 
Fibrils 
37°C 
N/A Dominant during 48 
hours: 
Parallel !-sheets 
  
(moderate stability) 
Dominant during 48 
hours: 
Parallel !-sheets 
Unordered 
(moderate stability) 
 
 100 
A simple assessment of Aß1-40 and Aß1-42 aggregation in oligomeric and 
fibril formation conditions shows how the likelihood of stability of the process 
flips.  Oligomers of Aß1-40 reach stability much faster than oligomers of Aß1-42 
while the opposite is true for the fibrillar species where Aß1-42 reaches stability 
considerably faster than fibrils formed by Aß1-40 peptide. 
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CHAPTER 5 
MONOCLONAL ANTIBODIES MODIFY FIBRILLOGENESIS 
  
The main goal of this study was to elucidate and analyze the deviation 
from a typical fibrillization process caused by targeting Aß peptide monomers 
and oligomers in solution (before fibrillization occurs) with different anti-Aß 
monoclonal antibodies (mAb).  In addition to the two isoforms, the equimolar 
mixture of the Aß1-40 and Aß1-42 (Aß40/42) was studied.  The rationale of this 
relates to the idea of having antibodies with different specificities that would 
better target the peptide mixture.  All the experiments were performed at 37°C 
and at a substoichiometric molar ratio of 1 to 1000 (antibody to peptide). 
 
5.1. Summary 
 In this chapter, the effects of antibodies were studied at a condition close 
physiological conditions in the brain.  For this, temperature was kept constant at 
37°C, and solutions were kept at pH 7.4.  A 1:1000 antibody to peptide molar 
ratio was chosen to approximate therapeutic conditions. The antibodies were 
applied to monomers and oligomers in solution (with exception of the first study 
using 6E10 and 2H6 on preformed fibrils) at the initial stage of the Aß40/42  
fibrillization process. 
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It is worth mentioning, that the oligomeric species of Aß peptide is 
recognized by different groups as the toxic specie from the aggregation process, 
due to its reactivity [15, 17-20, 87, 90-92], suggesting this species as a possible 
effective target for the antibody application.  
Table 6 describes the specificity for the monoclonal antibodies tested in 
this study. Briefly, 6E10 can bind to the N-terminus of either Aß1-40  or Aß1-42 
peptide, 2H6 binds to the C-terminus of Aß1-40 ; 4G8 binds to the mid domain (17-
24) of either Aß1-40  or Aß1-42; and finally mIgG2b with not specificity to neither 
Aß1-40 or Aß1-42 peptides, that is used as a control antibody.  
 
Table 6. Specificity and Binding of Antibodies Tested  
Antibody Specificity  Binding 
6E10 n-term 1-16 Aß 1-x 
2H6* c-term 35-40 40 only 
4G8 (Signet Dedham, MA) mid-domain 17-24 Aß 17-x 
mIgG2b*3  Control antibody does not bind Aß species 
* Antibodies provided by Rinat-Pfizer 
 
All the antibodies tested were provided either by David Morgan’s group 
(USF Health Byrd Alzheimer’s Institute) or Rinat-Pfizer (San Francisco, CA) 
directly.  
 
 
                                            
3 Antibody raised against a pseudomonas aeruginosa antigen. 
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5.2. Protocols and Methods 
 ATR-FTIR, AFM, and TEM analytical techniques were used in the same 
capacity as described in previous chapters. Moreover, some of the experiments 
with antibodies were also characterized using Western Blot.   
 
5.2.1. Antibody-Peptide Solution  
 An equimolar mixture of Aß1-40 and Aß1-42 (Aß40/42) was first prepared as 
explained in section 4.1.4. In brief, Aß1-40 and Aß1-42 peptides were prepared 
separately. Each peptide’s film was redissolved with DMSO and diluted to        
100 #M with 0.01 M PBS.  These two solutions were then combined in a 1 to 1 
molar ratio stock solution. 
Amyloid peptides were incubated with each antibody from the beginning of 
the fibril formation process. However, 6E10 and 2H6 antibodies were also tested 
against 5 days preformed fibrils.  
 
5.2.1.1. Effects of Low Antibody Concentration on Aß40/42 Fibrils 
 Amyloid-ß peptide fibrils were prepared following the protocol described in 
5.2.1. The Aß40/42 solution at 100 #M was aliquoted in three portions; one aliquot 
was injected in the ATR-FTIR flow cell, where the aggregation was monitored 
over time; the second portion was subdivided in different vials, each 
corresponding to different incubation times, later analyzed by AFM and TEM. The 
third portion was incubated for later addition of antibody (at day 5) and analyzed 
by AFM and TEM at different time over 5 days after antibody addition. Hence, the 
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processes of fibril formation and antibody addition were verified with ATR-FTIR 
spectroscopy, AFM and TEM. The antibody was added in a molar ratio of 1 to 
1000, antibody to peptide, all the samples were incubated at 37°C. 
The control solution for this study was the equimolar mixture of Aß40/42 
peptides incubated with no addition of antibody for a period of 10 days at 37°C. 
 
5.2.1.2. Targeting Aß40/42 Monomers and Oligomers with Low Concentration 
of Different Monoclonal Antibodies  
As in section 5.2.1.1, each solution was prepared using a 1:1000 
substoichiometric molar ratio, antibody to amyloid peptide respectively. As 
described previously, the peptide’s film was first redissolved with DMSO   (0.2 
mM) and diluted to 100 #M in 0.01 M PBS (pH 7.4), Aß1-40 and Aß1-42 peptides 
were prepared separately and then the solutions were combined in a 1 to 1 molar 
ratio.  Immediately after combining the two peptide solutions the antibody was 
added to the peptide’s mixture in a molar ratio 1:1000 of antibody to peptide.  
The solution antibody-peptide was divided in two portions each incubated 
at 37°C. The first portion of this solution was injected in the ATR-FTIR flow cell 
accessory where it was monitored over 10 days of incubation (by spectroscopy). 
The other portion of the antibody-peptide solution was subdivided for AFM, TEM, 
and Western Blot analysis. Samples were collected over a period of 10 days.  
The control for this study was a solution of Aß40/42 peptide prepared with 
an antibody (mIgG2b) with not specificity to either peptide.  
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In addition to the control above, and to prove that our results correspond 
to the antibody-peptide interaction rather than the single antibody and peptide 
contribution, a predicted model of secondary structures was calculated, this by 
mathematical adding the secondary structures calculated for Aß40/42 peptide 
incubated without antibody and the secondary structures of antibodies 2H6 and 
6E10 when incubated alone over the same period of time. This is Aß40/42 + 2H6 
and Aß40/42 + 6E10. The Aß40/42, 2H6, and 6E10 controls were solutions prepared 
and incubated as if they were combined in a 1:1000 antibody to peptide system.  
The antibodies used for these experiments (see Table 6) were received 
from the provider dissolved in PBS solution at variable concentrations (1-2 
mg/ml), hence calculations of the appropriate volume of antibody were performed 
to assure the same molar ratio for all experiments. In order to avoid antibody 
contamination and unnecessary freeze-unfreeze cycles, all the antibody stock 
solutions were aliquoted (in 5 portions) and kept at -20°C once received from the 
provider. Prior to use, 1 of the 5 vials containing the antibody was retrieved from 
the freezer and allowed to equilibrate to 25°C.  
    
5.2.2. AFM and TEM Characterization 
 AFM and TEM assisted to determine the state of aggregation of the 
peptides in contact with antibodies. In the initial state of aggregation, the peptide 
tends to spread fairly uniformly across the substrate where it is deposited.   
However, as the incubation time increases, and peptides aggregate into  
fibrils, it becomes challenging for the nanoscale-size tip of the AFM to depict 
 106 
where fibrils are located on the substrate.  At this point, it is better to combine 
TEM with AFM to determine the aggregation state and to examine the sample’s 
surface distribution. Therefore, some results illustrating the morphology and/or 
topology of the samples will be shown with both techniques (TEM adapted to the 
AFM scale). 
 
5.2.3.  ATR-FTIR Analysis 
 The background solution used for these studies was the solvent in which 
the peptides/antibody systems were prepared, that was 2% DMSO to 98% 0.01M 
PBS (v/v). Therefore, all the collected spectra represent the changes of 
secondary structures of the antibody-peptide mixture. 
 
5.2.4.  SDS-PAGE and Western Blot Analysis 
SDS-PAGE and immunoblotting was performed as described by Dahlgren 
et al., 2002 [19].  Briefly, individual aliquots of the stock solution collected at the 
testing times were centrifuged at 14,000g for 10 min at 4°C in order to remove 
large aggregates such as potential fibrils in the supernatant.  Iced cold Millipore 
water was used to dilute the monomer- and oligomer-containing A!40/42 (or mAb-
Aß mixture) supernatant at 1:5 ratio and mixed with a buffer. Note that there is no 
heating nor use of additional reducing agents. These sample were then 
combined with a 12 % Bis-Tris NuPage gel using MES as the running buffer 
(Invitrogen, US). See Blue pre-stained molecular mass markers were run on 
each gel (Invitrogen, US). Peptides separated at 160 V for 1 h and subsequently 
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transferred to 0.22 mm PVDF membranes at 35 V for 1hr. The membranes were 
blocked for 1 hour at room temperature (RT) using 5 % non-fat dry milk 
(International, Diagnostics Group, UK) in 20 mmol/LTris-buffer, pH 7.6, with 137 
mmol/L NaCl and 0.05 % (w/v) Tween 20. Subsequently, the membranes were 
incubated with a primary antibody in blocking buffer overnight at 4°C. The 
primary antibody 6E10 (a mouse monoclonal antibody directed against the 
human A! amino acid residues 1-17) was used at a dilution of 1:1000. The 
membrane was then rinsed in Tris-buffer, pH 7.6, 137 mmol/L NaCl and 0.05 % 
(w/v) Tween 20 three times and incubated with secondary antibody solution of 
HRP-labeled rabbit antibodies against mouse IgG (diluted 1:2000) for 1 h at RT. 
Rinsing with 20 mmol/L Tris-buffer, pH 7.6, with 137 mmol/L NaCl and 0.05 % 
(w/v) Tween 20 was applied again. 
  Immunostained peptides were visualized using chemiluminescence, in 
accordance with the manufacturer’s recommendations (ECL, Amersham, 
Denmark). Western blots were scanned using a Fujifilm Lass 300 Intelligent dark 
box scanner, and band density of each blot was quantified within linear range of 
detection using AlphaEase software.  
 This immunnochemical analysis was used to monitor the presence of 
monomers and oligomers during the aggregation process. 
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5.3.  Results, Analysis and Discussions 
 The outline for subsequent sections is as follows: 5.3.1. the effects of 
6E10 and 2H6 antibodies on Aß40/42 pre-formed fibrils (at 5 days of incubation) 
are compared; 5.3.2. the effects 6E10 and 2H6 antibodies added at the 
beginning of the aggregation process (when only monomers and oligomers are 
present) are compared; and 5.3.3. the effects of 2H6, 6E10, and 4G8 antibodies 
are compared against mIgG2b, a non-specific antibody. 
 
5.3.1. Effects of Antibodies on Species of Aß40/42 Targeting the Peptides   
C-Terminus or N-Terminus 
 In this section, it is first shown the effects of 6E10 and 2H6 antibodies on 
fibrils pre-incubated for 5 days, testing a molar ratio of 1:1000 (antibody to 
peptide).  Then, these same antibodies were tested against an initial aggregation 
stage solution, were mainly oligomers and monomer were present.  
The rationale for comparing the effect of antibodies against fibrils or 
monomers+oligomers is to determine which species are more likely to be 
influenced by the addition of antibodies. It is desired that if an antibody is going to 
be used in passive immunization, it should be able to break preformed fibrils or to 
stop or prevent their aggregation in the first place. The effect of the antibodies in 
this study has been measured depending on how effective they are to induce 
antiparallel beta sheet structures or to decrease parallel beta sheets structures 
(those structures were associated with monomeric and fibril species, 
respectively, in Chapter 4). 
 109 
5.3.1.1. Effects of 6E10 and 2H6 on Aß40/42 Pre-Formed Fibrils 
As explained in previous sections, an equimolar mixture of Aß40/42 
peptides was used to form fibrils, and a substoichiometric molar ratio of 1:1000, 
antibody (either 6E10 or 2H6) to peptide respectively was used.  Figures 56 (a)-
(c) show the spectral evolution for amide I and II bands with respect to incubation 
time for the control system (Aß40/42 peptides mixture), the Aß40/42 + 6E10 antibody 
and the Aß40/42 + 2H6 antibody, respectively. These average spectra were 
obtained as described in the Chapter 3 (Section 3.3.1.3).  Briefly, continuous 
spectra corresponding to a selected time range were averaged into a single 
spectrum.  
As described above, at day 5, the antibody was added to a preformed fibril 
solution, indicated with an arrow (! +mAb) in the spectrum for the control 
(Aß40/42) peptide solution (Figure 56(a)).  It is worth mentioning that the 
background spectrum for Figures 56(b) and (c) was obtained from the control 
system at day five of incubation (e.g., prior to adding the antibodies).  Moreover, 
the Amide II band progression in Figure 55 shows a significant increase for the 
case when 6E10 antibody was added (Figure 56(b)). This means that 6E10 
antibody promoted surface adsorption of the peptides to the surface. This same 
band did not increase, and if anything, it shows a slight decrease  when 2H6 
antibody was added (Figure 56(c)). This implies that the preformed fibrils did not 
necessarily detach from the surface completely. Rather, it indicates that the fibrils 
attached to the surface were attacked by 2H6 antibody.  
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Figure 56.  Influence of Low Concentration Antibodies Targeting Aß40/42 Fibrils. 
Average spectra obtained at 37°C, amide I and II regions are shown for (a) the 
control mixture of Aß40/42 peptides, (b) 6E10 antibody added to Aß40/42 peptide 
mixture (1:1000). This antibody targets the N-terminus of both peptides, (c) 2H6 
antibody added to Aß40/42 peptide mixture (1:1000)., antibody with affinity  to the 
C-terminus of Aß1-40 peptide only.  The arrow shown in the spectrum for the 
control system at day 5 represents the point where antibodies were added to the 
peptide solution 
 
Figure 57 shows the most dominant secondary structures after the amide I 
region was deconvoluted for the control and the two cases of the antibody to 
peptide systems. Only parallel and antiparallel beta sheet structures are shown 
because these two structures provide the most relevant information regarding 
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any dissolution effect on the preformed peptides fibrils. Figure 57(a) shows that 
in the control system, parallel beta sheet structures increase continuously until 
they reach a plateau, which is when saturation has been reached after 48 h of 
incubation. Conversely, the progression for the peptide mixture +2H6 shows a 
peak with a maximum value at approximately 4 days of incubation in the parallel 
ß-sheet structures. Then, there is an abrupt decay of such structures, which 
implies that the antibody was able to render conformational changes tied to 
dissolution effects (Figure 57(a)). In the case of peptide mixture +6E10, the effect 
is better depicted in Figure 57(b), where the parallel beta sheet structures 
decreased to less than 5% of total structure content after day 3.  
Figure 57(d) shows the appearance of the fibrils found in the three 
samples after 10 days of incubation. It is observed that fibrils are still found in the 
case of 2H6 addition, but the morphology differs from the control system. That is, 
the fibril density is lower and fibril bundles are thinner than fibrils in the control 
picture (Top scan compare to bottom scan). In the case of 6E10, fibrils appear to 
be spread on the surface, but more abundant in comparison to the control 
system (+6E10 TEM Scan in Figure 57(d)).  
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Figure 57. Secondary Structure and Morphological Changes of Aß40/42 Fibrils 
after Combined with 6E10 or 2H6 Antibodies. Analysis of the secondary 
structures performed from the spectra shown in Figure 56.The values of the 
control (labeled as Aß40/42) peptides represent the change after the 5 days of 
incubation. The peptide mixture and the peptide mixture +antibody were further 
incubated for 10 days. (a) Comparison of the kinetics of parallel ß-sheet 
structures between the control and the peptide mixtures affected by 2H6 and 
6E10 antibodies in a molar ratio 1:1000. (b) Comparison of the parallel ß-sheets 
content for all three systems described above.  (c) Comparison of the antiparallel 
ß-sheet structures content with respect to incubation time for the systems 
described above.(d) TEM scans of the control after a total of 15 days of 
incubation at 37°C (Top), peptide mixture+6E10 (Middle), and peptide 
mixture+2H6 (Bottom). Both systems with the antibodies added were incubated 
for 10 days at 37°C 
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5.3.1.2. Effects of 6E10 and 2H6 on Aß40/42 Monomers and Oligomers 
The study on preformed fibrils on the previous section allows the 
statement that the effect of antibodies is limited on preformed fibrils. Continuing 
with this study, the effects taking place when antibodies are added at the initial 
stage of aggregation are presented. 
Figure 58 show the average spectra comparing the amide I and II regions 
of the control (Aß40/42), and Aß40/42 peptide treated with eider 6E10 or 2H6 
antibodies. The main differences are in the amide I region for the peptide 
mixture+2H6 antibody, where most of the secondary structures undergo sudden 
transformations at day three of incubation (Figure 59a and (b)). This implies that 
the fibril formation is dramatically disrupted. On the other hand, the amide II 
region shows significant growth. This increase in the peptide adsorption is 
expected since peptide structures undergoing conformational changes may not 
be able to go back into solution because they have been corrupted (Figure 58c). 
This finding is verified by analyzing the deconvolution of the spectra and the 
anatomic morphology of these spectra shown in Figures 59(a), (c) and (d), where 
the parallel beta sheet structures decrease, antiparallel beta sheet structures 
increase, and surface globular aggregates appear instead of fibrils. Note that 
even though antiparallel beta sheets content increased, peptide aggregation on 
the surface was relatively high.  As for the case of having peptide mixture+6E10 
antibodies, the Amide I and II regions follow the control system behavior (Figure 
58(b) and Figure 59(a)-(c)). Therefore, this antibody was unable to prevent the 
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fibrillization process under these conditions and did not prevent peptide 
adsorption to the surface since Figure 59d shows that fibrils were still formed. 
 
 
Figure 58. Monitoring Aß40/42 Fibrillization Process from the Beginning of the 
Incubation Process with N-Terminus and C-Terminus Antibodies. Spectra were 
collected at 37°C. Amides I and II changes for (a) Aß40/42 control system (b) 6E10 
added to the beginning of the incubation process ofAß40/42 peptides (1:1000 
molar ratio). This antibody targets the N-term of both Aß40 and Aß42 peptides. (c) 
2H6 antibody incubated with Aß40/42 peptides. 2H6 is affined to the C-term of the 
Aß1-40 peptide 
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Figure 59. Effects of 2H6 and 6E10 Antibodies on Aß40/42 Monomers + 
Oligomers. (a) Compares the parallel ß-Sheet structures evolution for the control 
system and for when antibodies where added to the peptide mixture, (b) 
Compares the parallel ß-sheets content, (c) Compares the antiparallel ß-sheet 
content , (d) AFM images representing the morphology of the fibrils immediately 
after antibody addition and after 10 days of incubation for the control system 
(Top),  and for the aggregates formed with 6E10 (mid) and +2H6 (Bottom) 
addition 
 
In order to investigate the changes in the initial species of the fibrillization 
process, that is, monomeric and oligomeric species, Western Blot analysis was 
also done to these samples. Results are shown in Figure 60. Figure 60(a) shows 
the results from Western Blot analysis performed on samples at the same 
conditions as in Figure 58. That is, Aß40/42 (control), Aß40/42 + 6E10, and Aß40/42 + 
2H6. Figure 59(b) shows the AlphaEase analysis of the soluble species 
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(monomers, low molecular weight (LMW) oligomers, and high molecular weight  
(HMW) oligomers). Note that monomers and oligomers disappear from the 
solution after day 2 for all three cases. This indicates that during the incubation 
process, fibrillization is forced and monomeric as well as oligomeric species 
undergo configurational changes into much higher molecular weight structures, 
which are transparent to/undetected by this technique (fibril aggregates). 
However, the HMW oligomeric species abruptly increases after day 3 for the 
case of Aß40/42 peptide mixture treated with 2H6 antibody. This means that the 
antibody was able to reverse the production of fibril aggregates and induce the 
production of oligomers. Conversely, the control system and the samples treated 
with 6E10 antibody show that monomers and oligomers disappear and this 
antibody is not able to reverse this action. These results obtained with Western 
Blot are in line with the data from ATR-FTIR spectroscopy and AFM/TEM 
topological studies as depicted in Figures 58 and 59.  
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Figure 60. Effect of 2H6 and 6E10 on Soluble Species of Aß40/42 Peptide 
Equimolar Mixture during Fibrillogenesis. (a) Western Blot of the control 
system(Aß40/42 ), Aß40/42 + 6E10 antibody, and Aß40/42 + 2H6 antibody.     (b) 
AlphaEase analysis of soluble species for Monomers (Right), low molecular 
weight (LMW) oligomers (Middle), and high molecular weight (HMW) 
oligomers(Left) 
 
5.3.2. Proving Suitability of Results 
Before continuing with this study, it is necessary to prove that the results 
obtained correspond to the antibody-peptide interaction rather than to a pure 
contribution of antibody of peptide separately.  
For this, different control solutions were ran over 10 days and analyzed. 
The control solutions were, Aß40/42 with no antibody addition, antibody 6E10, 
and antibody 2H6.  In order to prove the results presented here, the secondary 
structures corresponding to peptide + 2H6, peptide + 6E10, and peptide + 
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average of 6E10 and 2H6 were mathematically added.  The results show (Figure 
61) that when comparing to the experimental data, the secondary structure 
kinetics is completely different from the predicted values.  Thus depicting 
completely different behaviors. 
 
 
Figure 61. Comparison of Predicted Secondary Structures vs. Experimental 
Structures. (a) Predicted behavior for the average values of antibodies control 
6E10 and 2H6 when added to Aß40/42 control. (b) Predicted behavior for the 
average values of antibodies control 6E10 when added to Aß40/42 control. (c) 
Predicted behavior for the average values of antibodies control 2H6 when added 
to Aß40/42 control. (d) Experimental values for 6E10: Aß40/42 at 1:1000. Control. (e) 
Experimental values for 2H6: Aß40/42 at 1:1000.  
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This study proves that when any antibody (that binds the peptide) is added 
to the peptide mixture, the resulting spectra correspond to the interaction 
antibody-peptide in solution, and not to the independent spectra. Hence, our 
results show a fair representation of the effect of antibodies on amyloid beta 
peptides during fibril formation or disruption. 
 
5.3.3. Effects of Antibodies on Aß40/42 Monomers and Oligomers 
This study compares the effects of antibodies on an initial system mainly 
composed by monomers and oligomers in solution. The study compares three 
antibodies that bind either or both peptide against a non specific antibody.  
The results in Figure 62 show the existence and increase of a peak 
centered in the parallel ß-sheet frequency region (1630cm-1) for the cases of the 
control, peptide treated with 6E10 and peptide treated with 4G8, when in  
comparison to the peptide treated with 2H6 this peak seems to decrease and 
with the shifting of peaks in other regions.  Once Figures 62(a)-(d) are 
deconvoluted and integrated, the comparison can have greater detail as shown 
in Figure 63(a)-(c), proving that from all the antibodies only when the peptide is 
treated with antibody 2H6, there is a noticeable decrease in parallel ß-sheets and 
an increase in antiparallel ß-sheets structures after day 3 of incubation. 
 In addition, Figure 63(d) compares the morphological appearance of the 
four systems under study, showing the formation of fibrils in the system of 
peptide treated with IgG2b, 6E10, and 4G8, when in the case of peptide treated 
with 2H6 amorphous aggregates are found rather than fibrils. 
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Figure 62.  Monitoring  Aß40/42 Fibrillization Process from the Beginning of the 
Incubation Process with N-Terminus and C-Terminus Antibodies. Spectra were 
collected at 37°C. Amides I and II changes for (a) Aß40/42 control system (b) 6E10 
added to the beginning of the incubation process ofAß40/42 peptides (1:1000 
molar ratio). This antibody targets the N-term of both Aß40 and Aß42 peptides. (c) 
2H6 antibody incubated with Aß40/42 peptides. 2H6 is specific to the C-term of the 
Aß1-40 peptide.  (d) 4G8 antibody incubated with Aß40/42 peptides. 4G8 has 
specificity to the mid domain of  both Aß1-40 and Aß1-42 peptide. 
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Figure 63. Effects of 2H6, 6E10, and 4G8 Antibodies on Aß40/42 Monomers+ 
Oligomers.  (a) Compares the parallel ß-Sheet structures evolution for the control 
system and for when antibodies where added to the peptide mixture, (b) 
Compares the parallel ß-sheets content , (c) Compares the antiparallel ß-sheet 
content , (d) AFM images representing the morphology of the fibrils immediately 
after antibody addition and after 10 days of incubation for the control system 
(Top),  and for the aggregates formed with 6E10, 4G8, and 2H6 (Bottom) 
addition.  
 
This study proves that it is possible to discern and evaluate the effect of 
antibodies by analyzing the content and evolution of secondary structures of the 
system, and that this results can be corroborated by the physical characterization 
of the sample using AFM and TEM. 
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5.4. Chapter Remarks  
 The experiments in this chapter tested various monoclonal antibodies with 
different specificity against Aß peptides.  Aß1-40 and Aß1-42 peptides were ratio in 
a molar mixture of 1 to 1, and for every case, the antibody to peptide molar ratio 
was 1 to 1000. 
2H6 antibody targeting the C-terminus of Aß1-40 decreased the content of 
parallel !-sheets and increased the content of antiparallel !-sheets, these results 
are summarized in Table 6.  The rise in the content of antiparallel !-sheets might 
indicate the presence of unstable Aß40/42 oligomeric species (Chapter 4, Table 5).  
The effectiveness of the evaluation methods was tested as a platform to 
evaluate the effects of antibodies used against amyloid peptides. 
In general, the use of antibodies to target Amyloid Beta during the 
fibrillization process seems to be more effective that targeting fully formed fibrils. 
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Table 7. Summary of Observations for the Antibodies Tested in this Chapter 
Antibody Specificity Observable Effect 
6E10 Aß1-40 and Aß1-42 
n-terminus (1-16) 
• No effect to preformed fibrils 
• No effect on secondary structure content 
• No effect on fibrillization process 
2H6 Aß1/40 
c-terminus (35-40) 
• Decrease Parallel !-sheet content (both on 
preformed and in fibrillization) 
• Increase antiparallel !-sheet content (only in 
fibrillization) 
• Limited Effect on preformed fibers 
• Stopped fibrillization only allowing oligomers 
4G8 Aß1/40 and Aß1/42 
Mid-domain (17-24) 
• No effect on secondary structure content 
• Stopped fibrillization only allowing oligomers 
mIgG2b Non-specific • No effect on secondary structure content 
• No effect on fibrillization process 
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CHAPTER 6 
MIMICKING THE NEURON MEMBRANE SURFACE 
 
6.1. Lipid Bilayer Membranes and their Relevance to Aß Plaque 
Formation  
Lipid bilayer membranes are an important element of living cells, 
supported by a network of structural proteins called the cytoskeleton. An 
important characteristic of lipid bilayer membranes is their natural fluidity, which 
allows free movement of lipid molecules on their own monolayer. This fluidity 
shows differences throughout the cell membrane, and varies depending on the 
composition of the principal molecules forming the lipid bilayer: phospholipids, 
cholesterol, and glycolipids. The biophysical characteristics of the lipid 
membrane also allow certain proteins to embed and anchor or penetrate through 
them. 
The Alzheimer’s disease A!-hallmark supposes the formation of 
extracellular A! plaques; these plaques are formed on the cell membrane by 
binding to membrane molecules and by partial insertion into the cell membrane. 
It is evident that altering the homeostasis of membrane components such as 
cholesterol, leads to accelerated plaque formation that might be related to the 
anchoring or the release of A! [93]. Besides the biological implications, the 
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biophysical role of higher cell membrane contents of cholesterol and other 
intramembrane components is yet not well understood. However, recent studies 
suggest that cholesterol and membrane rigidity might hinder A! penetration 
resulting in amyloid accumulation on cell membranes [94]. 
This chapter presents two methods for building in vitro lipid bilayers with 
the potential to be used as a platform for studying biophysical phenomena 
related to A! plaque formation on lipid bilayer membranes. Two techniques for 
creating lipid bilayers were explored: Langmuir-Blodgett deposition technique 
and self-assembled bilayer membranes from lipid vesicles. In both cases, the 
lipid bilayer membranes were deposited on a thin film of polyethylene glycol 
(PEG), which acts as a cushion layer to the lipid bilayers and serves to mimic 
membrane fluidity [95].   
The composition of model in vitro membranes can be made to mimic 
different conditions important to the understanding of A! plaque formation by 
reproducing in a monolithic way local characteristics of membrane domains. One 
of the challenges encountered in reproducing cell membrane characteristics in 
vitro lipid bilayer is reproducing membrane fluidity; this can be overcome by using 
a cushion layer below the in vitro lipid membrane. 
 
6.2.    Soft-Support Layer Using Polyethylene Glycol 
Polyethylene glycol (PEG) is an amphiphilic oligomer used to build the 
soft-supported layer. PEG is a linear or branched neutral polyether that is soluble 
in water and most organic solvents. The following is the chemical formula for 
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PEG: HO-(CH2CH2O)n-CH2CHOH. PEG is utilized in this study because its 
physicochemical properties allow its use as a cushion substrate or coating 
polymer, and it has been a part of previous studies by our group [96]. When in 
aqueous solution, PEG rejects other polymers and proteins, and can form two-
phase systems with other polymers. This property is based on its molecular 
conformation in aqueous solution, whereby PEG exposes uncharged hydrophilic 
groups and shows very high surface mobility (steric exclusion).  
PEG can also be used to coat surfaces with very little chemistry 
modification to these surfaces. When surfaces are coated with PEG, they 
become hydrophilic and protein rejecting. This protein-rejecting characteristic of 
PEG makes it of value as a cushion layer under a lipid bilayer, as it would reduce 
the probability of proteins adhering to the substrate underneath the lipid bilayer 
membrane. Additionally, when chemically attached to a substrate, PEG 
maintains its biological and biocompatible properties. For all these reasons, PEG 
is an attractive substrate for using it as a support or cushion layer to increase in 
vitro fluidity of lipid bilayer membranes.   
  
6.2.1. Construction of the Soft-Support Layer Using PEG 
Following a protocol developed by Alcantar et al. in 2000 [97], a polished 
glass surface (rectangular hemacytometer cover glass, 12-519-10, Fisher Sci)  
was activated by submerging it in a 10 % w/v sodium hydroxide (NaOH, 1310-73-
2, Acros Organics) solution and sonicating (Model FS30, Fisher Sci.) it for 5  
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minutes. During the surface activation of polished glass, silanol groups (Si-OH) 
are produced at the solid-air interface (Figure 64). 
 The glass was retrieved from the NaOH solution and cleaned by rinsing it 
multiple times with Millipore water.  Ultrapure nitrogen was then applied to 
remove any water traces until the surface was completely dry. The activated 
glass surface was then submerged in the polyethylene glycol (PEG, 400 Da, 
P3265-500G, Sigma) for one hour at 100°C.  This resulted in the PEG being 
grafted to the surface of the activated polished glass (Figure 64.b).  This process 
occurs through a reaction between the end alcohol groups of the PEG molecules 
with the Si-OH molecules on the activated glass (Figures 64.a and 64.b).  
 
                             (a)                                                     (b)     
Figure 64. PEG Cushion Layer Construction. (a) During the surface activation 
of polished glass, silanol groups (Si-OH) are produced at the solid-air interface. 
(b) Schematic of the PEG surface grafting reaction, where silanol groups on 
the surface of the activated polished glass lose the hydrogen and forms water 
with the end hydroxyl group of the PEG molecules.  This result in the PEG 
being grafted to the surface of the activated polished glass. 
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The PEG grafted glass was retrieved from the PEG solution while still hot 
and immediately rinsed avoiding direct contact with the water flow.   Finally, the 
surface was dried by gently exposing it to a flow of ultrapure nitrogen. 
 
6.3. Lipid Bilayer Construction Techniques 
 
6.3.1.  Langmuir-Blodgett Deposition Technique 
This technique is used to deposit multiple organized and compact layers, 
one monolayer at a time. Any organic or inorganic molecule of amphiphilic nature 
can be deposited [98, 99]. Typically, a bed of water is used as the initial surface 
for deposition (subphase) in which the molecules to be deposited are gently 
placed. For this, a suitable solvent with lower density than the subphase (and 
with high vapor pressure) is used to dissolve the molecules.  This solvent is 
easily evaporable leaving a monolayer of the molecule of interest on the water’s 
surface.  
Once a monolayer of the molecule is formed on the subphase, the 
deposition takes place by slowly pulling out a previously submerged substrate, 
where the monolayers will be deposited in an upward followed by a downward 
direction.  These movements are perpendicular to the subphase surface (Figure 
65.a).  
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This technique is extremely simple and allows deposition of a single layer, 
bilayers, or multiple layers one at a time. Depending on the orientation of the 
amphiphilic molecule layers with respect to the substrate and to each other, the 
deposition can take one of three forms: X-type, Y-type, or Z-type (Figure 65.b). 
 
Figure 65. Langmuir-Blodgett Deposition Technique. (a) Schematic of the 
deposition methodology. (b) Types of deposition based on the order of layers. 
 
The Langmuir-Blodgett (LB) trough (Figure 66) requires an environment 
completely free of contamination to avoid particles clinging to the surface. These 
particles can contaminate and perturb the deposition quality. The trough is 
located inside a laminar flow cabinet to avoid potential contamination.  However, 
the airflow is turned off during lipid deposition in order to protect the trough from 
the environment. When necessary, Millipore water and sometimes organic 
 130 
solvents (for instance: chloroform) are used to clean the trough. A common 
indicator of cleanliness is the absence of air bubble formation.  The presence of 
bubbles with the addition of water indicates potential contamination. Hence, 
bubbles are eliminated by suction. 
 
Figure 66.  Langmuir-Blodgett Trough. The principal components of the 
trough are highlighted in this photo. 
 
The LB trough is connected to a computer system, and is run by software 
that allows the control of parameters such as surface area, superficial tension, 
and substrate deepness necessary for the actual deposition. The area, 
deposition pressure, and lipid concentration used for the depositions are chosen 
based on calibration experiments that are run beforehand and are a function of 
the lipid’s nature. 
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6.3.1.1. Layer-by-Layer Lipid Membrane Construction 
Lipid bilayers composed of 1,2-Distearoyl-sn-Glycero-3 
Phosphoethanolamine (DSPE, 850715X, Avanti Polar Lipids Inc.) were deposited 
onto the grafted PEG layer using the Langmuir-Blodgett deposition technique (LB 
trough, Model 611D, Nima Technology) as explained earlier in this chapter. The 
polished glass surfaces containing the soft-supported PEG layer were kept inside 
of a laminar flow cabinet (Class 100) to minimize contamination. 
The initial uncompressed surface area was fixed at 300 cm2. The lipids 
were compressed using a LB barrier speed of 25 cm2/min. The parameters used 
for this experiment, such as area, deposition pressure, and lipid concentration, 
were developed in a previous study [100].  A volume of 100 #L of DSPE was 
dissolved in chloroform  (HPLC  grade,  67-66-3,  Acros  Chemicals)  at  a  
concentration of 15 #g/#L. This solution was gently poured on the air/water 
interface using a gas tight Hamilton syringe (allowing 5 minutes for the solvent to 
evaporate).  During  the  process  of  deposition,  the surface pressure was kept 
constant at 30 mN/m. The process of deposition of the first lipid monolayer took 
place by dipping the activated polished glass with the PEG layer at a velocity of 2 
cm/min; the second lipid layer is deposited when the dipping motion is reversed, 
removing the glass from the trough and placed in a fluid reservoir for 
transportation (Figure 67). 
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Figure 67. Schematic of Lipid Bilayer Construction. (a) Schematic of first lipid 
monolayer deposited on the cushioned layer (PEG).  (b) Representation of the 
soft-supported lipid bilayer. Hydrophilic and hydrophobic domains are shown c. 
A double layer of lipid is deposited on top of the PEG layer using Langmuir-
Blodgett deposition technique. 
 
6.3.1.2. Soft-Supported Lipid Bilayer Characterization: Surface Topography 
Atomic Force Microscopy (AFM, MFP-3D, Asylum Research, Santa 
Barbara, CA) was used to physically characterize the surface 
topography/topology of the soft-supported lipid bilayer membranes. Tapping 
mode was used to scan the surfaces, which were at all times submerged in 
deionized water to preserve the integrity of the lipid bilayer. The cantilevers used 
had typical spring constant < 1 N/m. Scan sizes were 10x10 #m. (Figure 68).  
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Figure 68. Characterization of Soft-Supported Lipid Bilayer Membrane.           
(a) RMSR change at different steps of construction. (b) AFM images (0.5x0.5-
#m x-y scan size) at the different steps of the lipid bilayer assembly 
 
The lipid bilayer membranes were kept in contact with saturated lipid 
solution at all times to avoid air exposition, which could consequently cause 
damage to the samples. 
While LB is a simple and very reliable technique that allows deposition of 
homogenous monolayers, there are some limitations to this technique.   First, the 
substrate geometry has to be open and flat, second, the size of the substrate 
cannot be greater than 4 cm x 4 cm, and third, the transfer from the LB-trough 
(where the deposition takes place) to a container is difficult because any 
exposure of the bilayer to the air would destroy it.  This makes it difficult to store 
and unsuitable for certain characterization techniques (like closed ATR-FTIR flow 
cell).  Therefore, other methods to construct lipid bilayers must be considered, as 
is the case of vesicle based self-assembled lipid bilayers. 
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6.3.2. Vesicle Based Self-Assembled Lipid Bilayers 
Vesicle self-assembly technique provides an attractive alternative to 
overcome the limitations of the LB lipid deposition technique, such as size and 
geometry of the starting substrate, and difficult handling. 
The process consists of the spontaneous fusion of small unilamellar 
vesicles [101] onto a surface substrate. Vesicles are made of lipid aggregations 
when they are forced to associate in cores as micelles for instance (unilamellar) 
at controlled media conditions. 
A general methodology is to dissolve the lipids in a solvent, i.e. 
chloroform, and then, the lipid in suspension is placed in a rounded flask. The 
solvent is left to evaporate overnight and vacuum for 4 hours before further 
preparation. Once the film is completely dry, water is used to hydrate the film by 
heating and gently agitating it; once the transition temperature of the lipid is 
overcome the lipid will completely be dissolved. The last step in the preparation 
of vesicles is to slowly cool down the solution allowing the lipids to organize, 
resulting in vesicles formation. The deposition by self assembly technique, is 
accomplished by the interaction between the prepared vesicles and the treated 
surface substrate. This interaction burst the vesicles and drives a self-assembled 
lipid bilayer formation.  
 
6.3.2.1. Self-Assembled Lipid Bilayers from Vesicles 
As a second stage of this study, the formation of lipid bilayer membranes 
by self-assembly technique was performed.  
 135 
Lipid bilayers were prepared with the same lipid used in the Section 
6.3.1.1.: 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE). Following 
the principles explained in the previous section, for this study the vesicles were 
prepared by using 2 mg of lipids dissolved in CHCl3. The solvent was evaporated 
from the lipid solution using an ultrapure stream of nitrogen. The lipids were then 
hydrated for 20 minutes (in a concentration of 2 mg/ml in Millipore water) at a 
temperature above their highest transition temperature (100°C). 
In the next step, the solution was sonicated 5 times for periods of 2 
minutes (to form small unilamellar vesicles evenly distributed in size) [102].  
Finally, the vesicle solution was used to submerge the PEG grafted glass slides. 
The temperature was kept in the 90°C range, which was gradually lowered to 
allow vesicles to diffuse onto the PEG cushion layer. 
 
6.3.2.2. Self-Assembled Soft-Supported Lipid Bilayer Characterization 
In the preparation of self-assembled membranes using vesicles, the first 
step into characterization is the analysis of the vesicles size.  Using the dynamic 
light scattering (DLS) technique and instrument (Zetasizer Nano-S, Malvern, PA). 
The second characterization step is the study of the surface topography of 
the bilayer, and as explained for membranes deposited with LB, this surface 
characterization is to be done with atomic force microscopy.  However, because 
the technique to provide the lipid bilayers using vesicles is still under 
investigation, only the characterization of the vesicles size was performed.  
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The results showed high instability in the formation of self-assembled lipid 
bilayers.  The sizes of the vesicles obtained, were highly variably in dimensions 
(as shown in Table 8), and they were between 485 nm and 2348 nm.   
 
Table 8. Dynamic Light Scattering. Results giving the sizes 
of the multilamellar vesicles formed 
Peak Particle’s Diameter (nm) 
1 2347.5 ± 401.9 
2             484.8 ± 189.3 
 
The presence of large vesicles is an inconvenience in the formation of the 
lipid bilayer with this method (the optimum size should be between 40 nm to 100 
nm). The lipid used in this study (DSPE), has a long hydrophobic tail, which 
determines first, the creation of rather stables and large vesicles. Second, 
causes a high transition temperature (100°C).  This high transition temperature is 
similar to the one required for PEG surface grafting, which could be altering this 
last process. These reasons might explain the adverse results obtained for this 
particular lipid. 
In order to overcome the inconvenience in this technique, further testing 
should be accomplished using short hydrophobic tail lipids with low molecular 
weights, such as the following: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine 
(DPPC), Sphingomyelin (SM. Ceramide-1-Phosphocholine. Brain, Porcine), and 
1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC); all with MW between 730-
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790.  Additionally, cholesterol (Ovine wool, MW 387) can also be used in 
combination with these lipids to attain the same effect. 
 
6.4. Chapter Remarks  
In this study, a fluid cell membrane in vitro model was constructed to 
present a brain-like environment approach [103] with the purpose of providing a 
platform for future A! aggregation studies.  
In the first stage of this proposed project, lipid (DSPE) bilayers were formed 
on polyethylene glycol cushion support (PEG) using the Langmuir-Blodgett (LB) 
deposition technique [104, 105]. The PEG layer was successfully used as a 
stabilizer for the bilayers. It was observed that the PEG cushion layer offered 
high mobility to the lipid bilayer membrane (Figure 68). Also, the PEG layer was 
used to support self-assembled lipid bilayers formed from small unilamellar 
vesicles, an alternative technique to prepared lipid bilayers. 
Two important characteristics make this model a potential good platform 
for in vitro A! aggregation studies: First, the high fluidity provided by the cushion 
PEG layer underneath the lipid bilayer [105] gives the system fluidity that better 
represents that of cell membranes in mammalian cells. Second, protein exclusion 
characteristic of PEG also prevents proteins such as A! from breaching the lipid 
bilayer and adsorbing directly on the substrate; this property makes this platform 
also ideal for studies involving antibody-peptide interactions by confining these to 
the surface of the lipid bilayer. 
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CHAPTER 7 
CONCLUSIONS  
 
Alzheimer disease (AD) represents the main leading cause of dementia 
typically among individuals over the age of 65. As life expectancy increases (76 
year in 2006), also does the number of AD cases increases. As of today the 
number of AD cases worldwide is approximately 26 million of individual affected 
by the disease; and this number is estimated to increase to 106 million of cases 
by the year 2050.  
AD is known to affect the cognitive function, alter the social behavior and 
body motor skills, among other affections related to the nervous system. 
Nowadays, the causes of Alzheimer disease and onset mechanisms are yet 
unclear. There are still pieces missing in the puzzle to fully understand the 
disease and discern effective therapies to avoid and eradicate AD.  
From the pathology of the disease, are known three hallmarks commonly 
found in patients with AD, the extracellular formation of amyloid beta (Aß) 
plaques, the presence of intracellular neurofibrillary tangles, and finally the 
neuronal death.  The hypothesis that gathers these hallmarks (amyloid 
hypothesis) to explain the possible mechanism states that imbalance on the 
catabolic process of Aß peptide leads to its accumulation forming neuronal 
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plaques that trigger the formation of intracellular neurofibrlillary tangles and finally 
terminate the neurons [51, 88, 89].  
This work was studies and characterizes the mechanisms involved in the 
process of Aß plaque formation and its possible clearance by using an 
immunotherapeutic approach. 
 Two isoforms of the amyloid beta peptide were investigated separately 
and combined in an equimolar mixture. These were, Aß1-40, and Aß1-42 peptides. 
These two Aß isoforms are the main component of the neuritic Aß deposits (Aß 
plaques) found in the brain of patients with AD. 
 In order to understand the process of aggregation, initial attention was 
rendered to the study and characterization of the different species involved in the 
aggregation process. When many species might be found during the process of 
aggregation, for the effects of this study the species were classified as 
monomeric, oligomeric, and fibrillar. 
It is relevant to mention that amyloid beta owes its name to the 
characteristic of its native secondary structure composition, which is mainly the 
ß-structure type. ß-structures or more commonly known as ß-sheet structures 
are structures composed by lateral connecting ß-strand structures, through 5 or 
more hydrogen bonds. ß-strands are extended parts of the peptide formed by 5 
to 10 amino acids.  
The ß-sheet structures can be either parallel or antiparallel, depending on 
the orientation of the strands forming the ß-sheet structures.   
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Understanding these molecular configurations was important to interpret 
the results obtained with ATR-FTIR spectroscopy; since, this technique allows 
monitoring the secondary structures change by detecting the interactions 
occurring through hydrogen bonding within and between the peptide molecules. 
There are different points of view and disagreements on which is the most 
energetically stable ß-strands configuration (parallel or antiparallel). However, the 
results in this work showed that the stability of these structural configurations 
highly depends on the peptide isoform under study.  For instance, it was 
observed that when Aß1-40 fibril were forming the dominant structural 
configuration (in percentage) present along the process was the antiparallel type, 
in addition to "-helix structures while parallel structures were reduced 
considerably. In contrast, in the case of Aß1-42 peptide fibrillization, the structural 
configuration of the parallel type seems to dominate the aggregation.   
When oligomeric species are formed the configuration of the strand 
structures also varied in accordance with the peptide, as for Aß1-40 oligomeric 
species, the dominating arrangement was the parallel type, flipping to antiparallel 
when the peptides are set to form fibrils, and as for the Aß1-42 oligomeric species 
the antiparallel arrangement seems to dominate (and a-helix) flipping to parallel 
configuration or rearrangement type. 
Results in this study also suggested that the combination of the two 
peptide isoforms shows competition between the secondary structures making 
the fibrils morphologically different (thicker) from the peptides alone. 
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This work included the addition of monoclonal antibodies (mAb) with 
specificity to Aß with the purpose to modify or reverse the fibrillization process.   
All experiments were carried out at close to physiological conditions (37°C and 
pH 7.4).  The antibodies used were chosen for their particular specificity to Aß 
peptides and some for their potential use in therapeutic settings.  These 
antibodies were 6E10 (binds the N-terminus of both peptide isoforms), 2H6 
(preferentially binds to the C-terminus of Aß1-40), 4G8 (binds the mid domain 
either isoform), and a control antibody mIgG2b that has no specificity for either 
Aß peptide. 
Preformed fibrils targeted with antibodies 6E10 and 2H6 suffer secondary 
structural change but not in a degree that allow fibril dissolution. The initial state 
of aggregation resulted a convenient phase for the addition of antibodies.  This is 
evidenced by experiments in which the target point for antibody addition where 
monomeric and oligomeric species.  This resulted in antibody binding and 
altering the fibrillization process (Chapter 6). This phenomenon was observed 
when in two cases under equal incubation conditions but varying the species 
targeted by the antibody.  Preformed fibrils in solution were not easily dissolved, 
but targeting monomer + oligomers in solution (at the initial fibrillization phase) 
resulted in an evident effect of the antibody causing the disruption of the 
fibrillization process. 
 This study points to the structural configuration of the ß-strands forming 
the ß-sheet structures as the key to understand and explain at the molecular 
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level the effects caused by antibodies to the different species of the peptides 
isoforms studied in this work.   
 The combination of the analytical techniques  (ATR-FTIR, AFM, TEM) 
allowed the testing and evaluation of the peptide characteristics during 
aggregation and allowed to explain the effects of antibodies observed when 
targeting the different species of the Aß peptides. 
Finally, it was possible to prepare a soft substrate mimicking the cell 
membrane’s surface (Chapter 7), laying the groundwork for future experiments.  
A polymeric film (PEG) grafted to SiO2 served as a cushion layer for the 
deposition of a double layer of lipids. Langmuir-Blodgett resulted as the 
preferential deposition technique due to the control on monolayer uniformity 
before and during the lipids deposition.  In the future, this membrane could be 
optimized by inserting other cell membrane molecules; such as cholesterol, other 
lipids, sugar groups, or proteins.  This interface could potentially serve to test the 
surface role on the process of plaque formation as function of rigidity, for 
instance varying the amount of cholesterol inserted in the bilayer membrane. 
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CHAPTER 8 
FUTURE DIRECTIONS 
 
The studies presented in this work leave a door open for new possible 
paths to investigate, as described below. 
• Measurement of surface energy of Aß peptide species, in particular 
oligomers and protofibrils, which are the intermediate species in the 
process of fibrillization, this can be performed with surface force 
apparatus (SFA). 
• The effects observed in the ATR-FTIR spectroscopic analysis can be 
used to investigate synthetic analogs to antibodies that act on Aß 
peptides. ATR-FTIR information can be utilized to detect secondary 
structure fingerprints in molecule screening processes. 
• Other amylogenic processes such as the hyperphosphorylation of Tau 
protein (other hallmark of AD) can be studied using the methods 
presented in this dissertation. 
• Complementary techniques could be used to study binding and rate of 
aggregation and dissolution to complement the ATR-FTIR such as 
quartz crystal microbalance (QCM). 
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• It is suitable to introduce polarized light to the ATR-FTIR spectrometer 
to produce more complete information in regards to the structural 
orientation of the molecules. 
• Lipid bilayer membrane construction by self-assembled vesicles can be 
improved by introducing a mixture of lipids with different tail lengths, 
which might allow a controlled system at lower temperatures more 
suitable for the preparation of these membranes. 
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Appendix A. Isoelectric Points of Aß Peptides  
 
 
 
 
 
Figure 69. Titration Curve of Aß1-40 Indicating its Isoelectric Point. Obtained from 
http://biophysics.cs.vt.edu/H++/ (Virginia Tech) using the Protein Data Bank for 
the peptide sequence. 
 
 
 
 
 
 
 
Figure 70. Titration Curve of Aß1-42 Indicating its Isoelectric Point. Obtained from 
http://biophysics.cs.vt.edu/H++/ (Virginia Tech) using the Protein Data Bank for 
the peptide sequence. 
 
 
 
 
 158 
Appendix B. ATR Crystals 
Table 9. Limitations and General Specifications of ATR Crystals  
Material n1 
LWL 
[cm-1] 
dp 
[#m] 
Swater 
[g/100g] 
pH 
Range 
Hardness 
[Kg/mm2] 
AMTIR 2.5 625 1.46 Insoluble 1-9 170 
Diamond/ZnSe 2.4 525 1.66 Insoluble 1-14 5,700 
Diamond/KRS-
5 2.4 250 1.66 Insoluble 1-14 5,700 
Germanium 4.0 780 0.65 Insoluble 1-14 550 
KRS-5 2.4 250 1.73 0.05 5-8 40 
Silicon 3.4 1500 0.84 Insoluble 1-12 1150 
Silicon/Znse 3.4 525 0.84 Insoluble 1-12 1150 
ZnS 2.2 850 2.35 Insoluble 5-9 240 
ZnSe 2.4 525 1.66 Insoluble 5-9 120 
n1 = refractive index of ATR crystal, LWL = long wave length cut-off, dp = depth 
of penetration at 1000 cm-1, Swater = Solubility in Water 
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